1
|
Hatrisse C, Macaire C, Hebert C, Hanne-Poujade S, De Azevedo E, Audigié F, Ben Mansour K, Marin F, Martin P, Mezghani N, Chateau H, Chèze L. A Method for Quantifying Back Flexion/Extension from Three Inertial Measurement Units Mounted on a Horse's Withers, Thoracolumbar Region, and Pelvis. Sensors (Basel) 2023; 23:9625. [PMID: 38139471 PMCID: PMC10747348 DOI: 10.3390/s23249625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 11/28/2023] [Accepted: 11/30/2023] [Indexed: 12/24/2023]
Abstract
Back mobility is a criterion of well-being in a horse. Veterinarians visually assess the mobility of a horse's back during a locomotor examination. Quantifying it with on-board technology could be a major breakthrough to help them. The aim of this study was to evaluate the accuracy of a method of quantifying the back mobility of horses from inertial measurement units (IMUs) compared to motion capture (MOCAP) as a gold standard. Reflective markers and IMUs were positioned on the withers, eighteenth thoracic vertebra, and pelvis of four sound horses. The horses performed a walk and trot in straight lines and performed a gallop in circles on a soft surface. The developed method, based on the three IMUs, consists of calculating the flexion/extension angle of the thoracolumbar region. The IMU method showed a mean bias of 0.8° (±1.5°) (mean (±SD)) and 0.8° (±1.4°), respectively, for the flexion and extension movements, all gaits combined, compared to the MOCAP method. The results of this study suggest that the developed method has a similar accuracy to that of MOCAP, opening up possibilities for easy measurements under field conditions. Future studies will need to examine the correlations between these biomechanical measures and clinicians' visual assessment of back mobility defects.
Collapse
Affiliation(s)
- Chloé Hatrisse
- Laboratoire de Biomécanique et Mécanique des Chocs (LBMC) UMR_T 9406, Université Gustave Eiffel, Université Claude Bernard Lyon 1, 69622 Lyon, France;
- CIRALE, USC 957 BPLC, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (C.M.); (E.D.A.); (F.A.); (H.C.)
- Laboratoire d’Innovation Ouverte en Technologies de la Santé (LIO), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada;
| | - Claire Macaire
- CIRALE, USC 957 BPLC, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (C.M.); (E.D.A.); (F.A.); (H.C.)
- Laboratoire de BioMécanique et BioIngénierie (UMR CNRS 7338), Centre of Excellence for Human and Animal Movement Biomechanics (CoEMoB), Université de Technologie de Compiègne (UTC), Alliance Sorbonne Université, 60200 Compiègne, France; (K.B.M.); (F.M.)
- Labcom LIM-ENVA, LIM France, 24300 Nontron, France; (C.H.); (S.H.-P.); (P.M.)
| | - Camille Hebert
- Labcom LIM-ENVA, LIM France, 24300 Nontron, France; (C.H.); (S.H.-P.); (P.M.)
| | | | - Emeline De Azevedo
- CIRALE, USC 957 BPLC, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (C.M.); (E.D.A.); (F.A.); (H.C.)
| | - Fabrice Audigié
- CIRALE, USC 957 BPLC, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (C.M.); (E.D.A.); (F.A.); (H.C.)
| | - Khalil Ben Mansour
- Laboratoire de BioMécanique et BioIngénierie (UMR CNRS 7338), Centre of Excellence for Human and Animal Movement Biomechanics (CoEMoB), Université de Technologie de Compiègne (UTC), Alliance Sorbonne Université, 60200 Compiègne, France; (K.B.M.); (F.M.)
| | - Frederic Marin
- Laboratoire de BioMécanique et BioIngénierie (UMR CNRS 7338), Centre of Excellence for Human and Animal Movement Biomechanics (CoEMoB), Université de Technologie de Compiègne (UTC), Alliance Sorbonne Université, 60200 Compiègne, France; (K.B.M.); (F.M.)
| | - Pauline Martin
- Labcom LIM-ENVA, LIM France, 24300 Nontron, France; (C.H.); (S.H.-P.); (P.M.)
| | - Neila Mezghani
- Laboratoire d’Innovation Ouverte en Technologies de la Santé (LIO), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC H2X 0A9, Canada;
| | - Henry Chateau
- CIRALE, USC 957 BPLC, Ecole Nationale Vétérinaire d’Alfort, 94700 Maisons-Alfort, France; (C.M.); (E.D.A.); (F.A.); (H.C.)
| | - Laurence Chèze
- Laboratoire de Biomécanique et Mécanique des Chocs (LBMC) UMR_T 9406, Université Gustave Eiffel, Université Claude Bernard Lyon 1, 69622 Lyon, France;
| |
Collapse
|
2
|
Ranfagni A, Marino F, Marin F. Spectral Analysis of Quantum Field Fluctuations in a Strongly Coupled Optomechanical System. Phys Rev Lett 2023; 130:193601. [PMID: 37243649 DOI: 10.1103/physrevlett.130.193601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 02/02/2023] [Accepted: 04/19/2023] [Indexed: 05/29/2023]
Abstract
With a levitodynamics experiment in the strong and coherent quantum optomechanical coupling regime, we demonstrate that the oscillator acts as a broadband quantum spectrum analyzer. The asymmetry between positive and negative frequency branches in the displacement spectrum traces out the spectral features of the quantum fluctuations in the cavity field, which are thus explored over a wide spectral range. Moreover, in our two-dimensional mechanical system the quantum backaction, generated by such vacuum fluctuations, is strongly suppressed in a narrow spectral region due to a destructive interference in the overall susceptibility.
Collapse
Affiliation(s)
- A Ranfagni
- Dipartimento di Fisica e Astronomia, Università di Firenze, via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
- European Laboratory for Non-Linear Spectroscopy (LENS), via Carrara 1, I-50019 Sesto Fiorentino (FI), Italy
- INFN, Sezione di Firenze, via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
| | - F Marino
- INFN, Sezione di Firenze, via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
- CNR-INO, largo Enrico Fermi 6, I-50125 Firenze, Italy
| | - F Marin
- Dipartimento di Fisica e Astronomia, Università di Firenze, via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
- European Laboratory for Non-Linear Spectroscopy (LENS), via Carrara 1, I-50019 Sesto Fiorentino (FI), Italy
- INFN, Sezione di Firenze, via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
- CNR-INO, largo Enrico Fermi 6, I-50125 Firenze, Italy
| |
Collapse
|
3
|
Sarhan FR, Colin E, Choteau B, Mansour KB, Marcellin F, Martineza EAR, Marin F, Dakpé S. Combined Surface Electromyography and Motion Capture for Quantitative Analysis of Facial Movements. Arch Phys Med Rehabil 2023. [DOI: 10.1016/j.apmr.2022.12.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2023]
|
4
|
Nadarajah R, Ludman P, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP, Budaj A, Dagres N, Danchin N, Delgado V, Emberson J, Friberg O, Gale CP, Heyndrickx G, Iung B, James S, Kappetein AP, Maggioni AP, Maniadakis N, Nagy KV, Parati G, Petronio AS, Pietila M, Prescott E, Ruschitzka F, Van de Werf F, Weidinger F, Zeymer U, Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy KV, Nedoshivin A, Petronio AP, Roos-Hesselink JW, Wallentin L, Zeymer U, Popescu BA, Adlam D, Caforio ALP, Capodanno D, Dweck M, Erlinge D, Glikson M, Hausleiter J, Iung B, Kayikcioglu M, Ludman P, Lund L, Maggioni AP, Matskeplishvili S, Meder B, Nagy KV, Nedoshivin A, Neglia D, Pasquet AA, Roos-Hesselink JW, Rossello FJ, Shaheen SM, Torbica A, Gale CP, Ludman PF, Lettino M, Bueno H, Huber K, Leonardi S, Budaj A, Milasinovic (Serbia) D, Brugaletta S, Appelman Y, Kunadian V, Al Mahmeed WAR, Kzhdryan H, Dumont C, Geppert A, Bajramovic NS, Cader FA, Beauloye C, Quesada D, Hlinomaz O, Liebetrau C, Marandi T, Shokry K, Bueno H, Kovacevic M, Crnomarkovic B, Cankovic M, Dabovic D, Jarakovic M, Pantic T, Trajkovic M, Pupic L, Ruzicic D, Cvetanovic D, Mansourati J, Obradovic I, Stankovic M, Loh PH, Kong W, Poh KK, Sia CH, Saw K, Liška D, Brozmannová D, Gbur M, Gale CP, Maxian R, Kovacic D, Poznic NG, Keric T, Kotnik G, Cercek M, Steblovnik K, Sustersic M, Cercek AC, Djokic I, Maisuradze D, Drnovsek B, Lipar L, Mocilnik M, Pleskovic A, Lainscak M, Crncic D, Nikojajevic I, Tibaut M, Cigut M, Leskovar B, Sinanis T, Furlan T, Grilj V, Rezun M, Mateo VM, Anguita MJF, Bustinza ICM, Quintana RB, Cimadevilla OCF, Fuertes J, Lopez F, Dharma S, Martin MD, Martinez L, Barrabes JA, Bañeras J, Belahnech Y, Ferreira-Gonzalez I, Jordan P, Lidon RM, Mila L, Sambola A, Orvin K, Sionis A, Bragagnini W, Cambra AD, Simon C, Burdeus MV, Ariza-Solé A, Alegre O, Alsina M, Ferrando JIL, Bosch X, Sinha A, Vidal P, Izquierdo M, Marin F, Esteve-Pastor MA, Tello-Montoliu A, Lopez-Garcia C, Rivera-Caravaca JM, Gil-Pérez P, Nicolas-Franco S, Keituqwa I, Farhan HA, Silva L, Blasco A, Escudier JM, Ortega J, Zamorano JL, Sanmartin M, Pereda DC, Rincon LM, Gonzalez P, Casado T, Sadeghipour P, Lopez-Sendon JL, Manjavacas AMI, Marin LAM, Sotelo LR, Rodriguez SOR, Bueno H, Martin R, Maruri R, Moreno G, Moris C, Gudmundsdottir I, Avanzas P, Ayesta A, Junco-Vicente A, Cubero-Gallego H, Pascual I, Sola NB, Rodriguez OA, Malagon L, Martinez-Basterra J, Arizcuren AM, Indolfi C, Romero J, Calleja AG, Fuertes DG, Crespín Crespín M, Bernal FJC, Ojeda FB, Padron AL, Cabeza MM, Vargas CM, Yanes G, Kitai T, Gonzalez MJG, Gonzalez Gonzalez J, Jorge P, De La Fuente B, Bermúdez MG, Perez-Lopez CMB, Basiero AB, Ruiz AC, Pamias RF, Chamero PS, Mirrakhimov E, Hidalgo-Urbano R, Garcia-Rubira JC, Seoane-Garcia T, Arroyo-Monino DF, Ruiz AB, Sanz-Girgas E, Bonet G, Rodríguez-López J, Scardino C, De Sousa D, Gustiene O, Elbasheer E, Humida A, Mahmoud H, Mohamed A, Hamid E, Hussein S, Abdelhameed M, Ali T, Ali Y, Eltayeb M, Philippe F, Ali M, Almubarak E, Badri M, Altaher S, Alla MD, Dellborg M, Dellborg H, Hultsberg-Olsson G, Marjeh YB, Abdin A, Erglis A, Alhussein F, Mgazeel F, Hammami R, Abid L, Bahloul A, Charfeddine S, Ellouze T, Canpolat U, Oksul M, Muderrisoglu H, Popovici M, Karacaglar E, Akgun A, Ari H, Ari S, Can V, Tuncay B, Kaya H, Dursun L, Kalenderoglu K, Tasar O, Kalpak O, Kilic S, Kucukosmanoglu M, Aytekin V, Baydar O, Demirci Y, Gürsoy E, Kilic A, Yildiz Ö, Arat-Ozkan A, Sinan UY, Dagva M, Gungor B, Sekerci SS, Zeren G, Erturk M, Demir AR, Yildirim C, Can C, Kayikcioglu M, Yagmur B, Oney S, Xuereb RG, Sabanoglu C, Inanc IH, Ziyrek M, Sen T, Astarcioglu MA, Kahraman F, Utku O, Celik A, Surmeli AO, Basaran O, Ahmad WAW, Demirbag R, Besli F, Gungoren F, Ingabire P, Mondo C, Ssemanda S, Semu T, Mulla AA, Atos JS, Wajid I, Appelman Y, Al Mahmeed WAR, Atallah B, Bakr K, Garrod R, Makia F, Eldeeb F, Abdekader R, Gomaa A, Kandasamy S, Maruthanayagam R, Nadar SK, Nakad G, Nair R, Mota P, Prior P, Mcdonald S, Rand J, Schumacher N, Abraheem A, Clark M, Coulding M, Qamar N, Turner V, Negahban AQ, Crew A, Hope S, Howson J, Jones S, Lancaster N, Nicholson A, Wray G, Donnelly P, Gierlotka M, Hammond L, Hammond S, Regan S, Watkin R, Papadopoulos C, Ludman P, Hutton K, Macdonald S, Nilsson A, Roberts S, Monteiro S, Garg S, Balachandran K, Mcdonald J, Singh R, Marsden K, Davies K, Desai H, Goddard W, Iqbal N, Chalil S, Dan GA, Galasko G, Assaf O, Benham L, Brown J, Collins S, Fleming C, Glen J, Mitchell M, Preston S, Uttley A, Radovanovic M, Lindsay S, Akhtar N, Atkinson C, Vinod M, Wilson A, Clifford P, Firoozan S, Yashoman M, Bowers N, Chaplin J, Reznik EV, Harvey S, Kononen M, Lopesdesousa G, Saraiva F, Sharma S, Cruddas E, Law J, Young E, Hoye A, Harper P, Balghith M, Rowe K, Been M, Cummins H, French E, Gibson C, Abraham JA, Hobson S, Kay A, Kent M, Wilkinson A, Mohamed A, Clark S, Duncan L, Ahmed IM, Khatiwada D, Mccarrick A, Wanda I, Read P, Afsar A, Rivers V, Theobald T, Cercek M, Bell S, Buckman C, Francis R, Peters G, Stables R, Morgan M, Noorzadeh M, Taylor B, Twiss S, Widdows P, Brozmannová D, Wilkinson V, Black M, Clark A, Clarkson N, Currie J, George L, Mcgee C, Izzat L, Lewis T, Omar Z, Aytekin V, Phillips S, Ahmed F, Mackie S, Oommen A, Phillips H, Sherwood M, Aleti S, Charles T, Jose M, Kolakaluri L, Ingabire P, Karoudi RA, Deery J, Hazelton T, Knight A, Price C, Turney S, Kardos A, Williams F, Wren L, Bega G, Alyavi B, Scaletta D, Kunadian V, Cullen K, Jones S, Kirkup E, Ripley DP, Matthews IG, Mcleod A, Runnett C, Thomas HE, Cartasegna L, Gunarathne A, Burton J, King R, Quinn J, Sobolewska J, Munt S, Porter J, Christenssen V, Leng K, Peachey T, Gomez VN, Temple N, Wells K, Viswanathan G, Taneja A, Cann E, Eglinton C, Hyams B, Jones E, Reed F, Smith J, Beltrano C, Affleck DC, Turner A, Ward T, Wilmshurst N, Stirrup J, Brunton M, Whyte A, Smith S, Murray V, Walker R, Novas V, Weston C, Brown C, Collier D, Curtis K, Dixon K, Wells T, Trim F, Ghosh J, Mavuri M, Barman L, Dumont C, Elliott K, Harrison R, Mallinson J, Neale T, Smith J, Toohie J, Turnbull A, Parker E, Hossain R, Cheeseman M, Balparda H, Hill J, Hood M, Hutchinson D, Mellows K, Pendlebury C, Storey RF, Barker J, Birchall K, Denney H, Housley K, Cardona M, Middle J, Kukreja N, Gati S, Kirk P, Lynch M, Srinivasan M, Szygula J, Baker P, Cruz C, Derigay J, Cigalini C, Lamb K, Nembhard S, Price A, Mamas M, Massey I, Wain J, Delaney J, Junejo S, Martin K, Obaid D, Hoyle V, Brinkworth E, Davies C, Evans D, Richards S, Thomas C, Williams M, Dayer M, Mills H, Roberts K, Goodchild F, Dámaso ES, Greig N, Kundu S, Donaldson D, Tonks L, Beekes M, Button H, Hurford F, Motherwell N, Summers-Wall J, Felmeden D, Tapia V, Keeling P, Sheikh U, Yonis A, Felmeden L, Hughes D, Micklewright L, Summerhayes A, Sutton J, Panoulas V, Prendergast C, Poghosyan K, Rogers P, Barker LN, Batin P, Conway D, Exley D, Fletcher A, Wright J, Nageh T, Hadebe B, Kunhunny S, Mkhitaryan S, Mshengu E, Karthikeyan VJ, Hamdan H, Cooper J, Dandy C, Parkinson V, Paterson P, Reddington S, Taylor T, Tierney C, Adamyan M, Jones KV, Broadley A, Beesley K, Buckley C, Hellyer C, Pippard L, Pitt-Kerby T, Azam J, Hayes C, Freshwater K, Boyadjian S, Johnson L, Mcgill Y, Redfearn H, Russell M, Alyavi A, Alyavi B, Uzokov J, Hayrapetyan H, Azaryan K, Tadevosyan M, Poghosyan H, Kzhdryan H, Vardanyan A, Huber K, Geppert A, Ahmed A, Weidinger F, Derntl M, Hasun M, Schuh-Eiring T, Riegler L, Haq MM, Cader FA, Dewan MAM, Fatema ME, Hasan AS, Islam MM, Khandoker F, Mayedah R, Nizam SU, Azam MG, Arefin MM, Jahan J, Schelfaut D, De Raedt H, Wouters S, Aerts S, Batjoens H, Beauloye C, Dechamps M, Pierard S, Van Caenegem O, Sinnaeve F, Claeys MJ, Snepvangers M, Somers V, Gevaert S, Schaubroek H, Vervaet P, Buysse M, Renders F, Dumoulein M, Hiltrop N, De Coninck M, Naessens S, Senesael I, Hoffer E, Pourbaix S, Beckers J, Dugauquier C, Jacquet S, Malmendier D, Massoz M, Evrard P, Collard L, Brunner P, Carlier S, Blockmans M, Mayne D, Timiras E, Guédès A, Demeure F, Hanet C, Domange J, Jourdan K, Begic E, Custovic F, Dozic A, Hrvat E, Kurbasic I, Mackic D, Subo A, Durak-Nalbantic A, Dzubur A, Rebic D, Hamzic-Mehmedbasic A, Redzepovic A, Djokic-Vejzovic A, Hodzic E, Hujdur M, Musija E, Gljiva-Gogic Z, Serdarevic N, Bajramovic NS, Brigic L, Halilcevic M, Cibo M, Hadžibegic N, Kukavica N, Begic A, Iglica A, Osmanagic A, Resic N, Grgurevic MV, Zvizdic F, Pojskic B, Mujaric E, Selimovic H, Ejubovic M, Pojskic L, Stimjanin E, Sut M, Zapata PS, Munoz CG, Andrade LAF, Upegui MPT, Perez LE, Chavarria J, Quesada D, Alvarado K, Zaputovic L, Tomulic V, Gobic D, Jakljevic T, Lulic D, Bacic G, Bastiancic L, Avraamides P, Eftychiou C, Eteocleous N, Ioannou A, Lambrianidi C, Drakomathioulakis M, Groch L, Hlinomaz O, Rezek M, Semenka J, Sitar J, Beranova M, Kramarikova P, Pesl L, Sindelarova S, Tousek F, Warda HM, Ghaly I, Habiba S, Habib A, Gergis MN, Bahaa H, Samir A, Taha HSE, Adel M, Algamal HM, Mamdouh M, Shaker AF, Shokry K, Konsoah A, Mostafa AM, Ibrahim A, Imam A, Hafez B, Zahran A, Abdelhamid M, Mahmoud K, Mostafa A, Samir A, Abdrabou M, Kamal A, Sallam S, Ali A, Maghraby K, Atta AR, Saad A, Ali M, Lotman EM, Lubi R, Kaljumäe H, Uuetoa T, Kiitam U, Durier C, Ressencourt O, El Din AA, Guiatni A, Bras ML, Mougenot E, Labeque JN, Banos JL, Capendeguy O, Mansourati J, Fofana A, Augagneur M, Bahon L, Pape AL, Batias-Moreau L, Fluttaz A, Good F, Prieur F, Boiffard E, Derien AS, Drapeau I, Roy N, Perret T, Dubreuil O, Ranc S, Rio S, Bonnet JL, Bonnet G, Cuisset T, Deharo P, Mouret JP, Spychaj JC, Blondelon A, Delarche N, Decalf V, Guillard N, Hakme A, Roger MP, Biron Y, Druelles P, Loubeyre C, Lucon A, Hery P, Nejjari M, Digne F, Huchet F, Neykova A, Tzvetkov B, Larrieu M, Quaino G, Armangau P, Sauguet A, Bonfils L, Dumonteil N, Fajadet J, Farah B, Honton B, Monteil B, Philippart R, Tchetche D, Cottin M, Petit F, Piquart A, Popovic B, Varlot J, Maisuradze D, Sagirashvili E, Kereselidze Z, Totladze L, Ginturi T, Lagvilava D, Hamm C, Liebetrau C, Haas M, Hamm C, Koerschgen T, Weferling M, Wolter JS, Maier K, Nickenig G, Sedaghat A, Zachoval C, Lampropoulos K, Mpatsouli A, Sakellaropoulou A, Tyrovolas K, Zibounoumi N, Argyropoulos K, Toulgaridis F, Kolyviras A, Tzanis G, Tzifos V, Milkas A, Papaioannou S, Kyriazopoulos K, Pylarinou V, Kontonassakis I, Kotakos C, Kourgiannidis G, Ntoliou P, Parzakonis N, Pipertzi A, Sakalidis A, Ververeli CL, Kafkala K, Sinanis T, Diakakis G, Grammatikopoulos K, Papoutsaki E, Patialiatos T, Mamaloukaki M, Papadaki ST, Kanellos IE, Antoniou A, Tsinopoulos G, Goudis C, Giannadaki M, Daios S, Petridou M, Skantzis P, Koukis P, Dimitriadis F, Savvidis M, Styliadis I, Sachpekidis V, Pilalidou A, Stamatiadis N, Fotoglidis A, Karakanas A, Ruzsa Z, Becker D, Nowotta F, Gudmundsdottir I, Libungan B, Skuladottir FB, Halldorsdottir H, Shetty R, Iyengar S, Bs C, G S, Lakshmana S, S R, Tripathy N, Sinha A, Choudhary B, Kumar A, Kumar A, Raj R, Roy RS, Dharma S, Siswanto BB, Farhan HA, Yaseen IF, Al-Zaidi M, Dakhil Z, Amen S, Rasool B, Rajeeb A, Amber K, Ali HH, Al-Kinani T, Almyahi MH, Al-Obaidi F, Masoumi G, Sadeghi M, Heshmat-Ghahdarijani K, Roohafza H, Sarrafzadegan N, Shafeie M, Teimouri-Jervekani Z, Noori F, Kyavar M, Sadeghipour P, Firouzi A, Alemzadeh-Ansari MJ, Ghadrdoost B, Golpira R, Ghorbani A, Ahangari F, Salarifar M, Jenab Y, Biria A, Haghighi S, Mansouri P, Yadangi S, Kornowski R, Orvin K, Eisen A, Oginetz N, Vizel R, Kfir H, Pasquale GD, Casella G, Cardelli LS, Filippini E, Zagnoni S, Donazzan L, Ermacora D, Indolfi C, Polimeni A, Curcio A, Mongiardo A, De Rosa S, Sorrentino S, Spaccarotella C, Landolina M, Marino M, Cacucci M, Vailati L, Bernabò P, Montisci R, Meloni L, Marchetti MF, Biddau M, Garau E, Barbato E, Morisco C, Strisciuglio T, Canciello G, Lorenzoni G, Casu G, Merella P, Novo G, D'Agostino A, Di Lisi D, Di Palermo A, Evola S, Immordino F, Rossetto L, Spica G, Pavan D, Mattia AD, Belfiore R, Grandis U, Vendrametto F, Spagnolo C, Carniel L, Sonego E, Gaudio C, Barillà F, Biccire FG, Bruno N, Ferrari I, Paravati V, Torromeo C, Galasso G, Peluso A, Prota C, Radano I, Benvenga RM, Ferraioli D, Anselmi M, Frigo GM, Sinagra G, Merlo M, Perkan A, Ramani F, Altinier A, Fabris E, Rinaldi M, Usmiani T, Checco L, Frea S, Mussida M, Matsukawa R, Sugi K, Kitai T, Furukawa Y, Masumoto A, Miyoshi Y, Nishino S, Assembekov B, Amirov B, Chernokurova Y, Ibragimova F, Mirrakhimov E, Ibraimova A, Murataliev T, Radzhapova Z, Uulu ES, Zhanyshbekova N, Zventsova V, Erglis A, Bondare L, Zaliunas R, Gustiene O, Dirsiene R, Marcinkeviciene J, Sakalyte G, Virbickiene A, Baksyte G, Bardauskiene L, Gelmaniene R, Salkauskaite A, Ziubryte G, Kupstyte-Kristapone N, Badariene J, Balciute S, Kapleriene L, Lizaitis M, Marinskiene J, Navickaite A, Pilkiene A, Ramanauskaite D, Serpytis R, Silinskiene D, Simbelyte T, Staigyte J, Philippe F, Degrell P, Camus E, Ahmad WAW, Kassim ZA, Xuereb RG, Buttigieg LL, Camilleri W, Pllaha E, Xuereb S, Popovici M, Ivanov V, Plugaru A, Moscalu V, Popovici I, Abras M, Ciobanu L, Litvinenco N, Fuior S, Dumanschi C, Ivanov M, Danila T, Grib L, Filimon S, Cardaniuc L, Batrinac A, Tasnic M, Cozma C, Revenco V, Sorici G, Dagva M, Choijiljav G, Dandar E, Khurelbaatar MU, Tsognemekh B, Appelman Y, Den Hartog A, Kolste HJT, Van Den Buijs D, Van'T Hof A, Pustjens T, Houben V, Kasperski I, Ten Berg J, Azzahhafi J, Bor W, Yin DCP, Mbakwem A, Amadi C, Kushimo O, Kilasho M, Oronsaye E, Bakracheski N, Bashuroska EK, Mojsovska V, Tupare S, Dejan M, Jovanoska J, Razmoski D, Marinoski T, Antovski A, Jovanovski Z, Kocho S, Markovski R, Ristovski V, Samir AB, Biserka S, Kalpak O, Peovska IM, Taleska BZ, Pejkov H, Busljetik O, Zimbakov Z, Grueva E, Bojovski I, Tutic M, Poposka L, Vavlukis M, Al-Riyami A, Nadar SK, Abdelmottaleb W, Ahmed S, Mujtaba MS, Al-Mashari S, Al-Riyami H, Laghari AH, Faheem O, Ahmed SW, Qamar N, Furnaz S, Kazmi K, Saghir T, Aneel A, Asim A, Madiha F, Sobkowicz B, Tycinska A, Kazimierczyk E, Szyszkowska A, Mizia-Stec K, Wybraniec M, Bednarek A, Glowacki K, Prokopczuk J, Babinski W, Blachut A, Kosiak M, Kusinska A, Samborski S, Stachura J, Szastok H, Wester A, Bartoszewska D, Sosnowska-Pasiarska B, Krzysiek M, Legutko J, Nawrotek B, Kasprzak JD, Klosinska M, Wiklo K, Kurpesa M, Rechcinski T, Cieslik-Guerra U, Gierlotka M, Bugajski J, Feusette P, Sacha J, Przybylo P, Krzesinski P, Ryczek R, Karasek A, Kazmierczak-Dziuk A, Mielniczuk M, Betkier-Lipinska K, Roik M, Labyk A, Krakowian M, Machowski M, Paczynska M, Potepa M, Pruszczyk P, Budaj A, Ambroziak M, Omelanczuk-Wiech E, Torun A, Opolski G, Glowczynska R, Fojt A, Kowalik R, Huczek Z, Jedrzejczyk S, Roleder T, Brust K, Gasior M, Desperak P, Hawranek M, Farto-Abreu P, Santos M, Baptista S, Brizida L, Faria D, Loureiro J, Magno P, Monteiro C, Nédio M, Tavares J, Sousa C, Almeida I, Almeida S, Miranda H, Santos H, Santos AP, Goncalves L, Monteiro S, Baptista R, Ferreira C, Ferreira J, Goncalves F, Lourenço C, Monteiro P, Picarra B, Santos AR, Guerreiro RA, Carias M, Carrington M, Pais J, de Figueiredo MP, Rocha AR, Mimoso J, De Jesus I, Fernandes R, Guedes J, Mota T, Mendes M, Ferreira J, Tralhão A, Aguiar CT, Strong C, Da Gama FF, Pais G, Timóteo AT, Rosa SAO, Mano T, Reis J, Selas M, Mendes DE, Satendra M, Pinto P, Queirós C, Oliveira I, Reis L, Cruz I, Fernandes R, Torres S, Luz A, Campinas A, Costa R, Frias A, Oliveira M, Martins V, Castilho B, Coelho C, Moura AR, Cotrim N, Dos Santos RC, Custodio P, Duarte R, Gomes R, Matias F, Mendonca C, Neiva J, Rabacal C, Almeida AR, Caeiro D, Queiroz P, Silva G, Pop-Moldovan AL, Darabantiu D, Mercea S, Dan GA, Dan AR, Dobranici M, Popescu RA, Adam C, Sinescu CJ, Andrei CL, Brezeanu R, Samoila N, Baluta MM, Pop D, Tomoaia R, Istratoaie O, Donoiu I, Cojocaru A, Oprita OC, Rocsoreanu A, Grecu M, Ailoaei S, Popescu MI, Cozma A, Babes EE, Rus M, Ardelean A, Larisa R, Moisi M, Ban E, Buzle A, Filimon G, Dobreanu D, Lupu S, Mitre A, Rudzik R, Sus I, Opris D, Somkereki C, Mornos C, Petrescu L, Betiu A, Volcescu A, Ioan O, Luca C, Maximov D, Mosteoru S, Pascalau L, Roman C, Brie D, Crisan S, Erimescu C, Falnita L, Gaita D, Gheorghiu M, Levashov S, Redkina M, Novitskii N, Dementiev E, Baglikov A, Zateyshchikov D, Zubova E, Rogozhina A, Salikov A, Nikitin I, Reznik EV, Komissarova MS, Shebzukhova M, Shitaya K, Stolbova S, Larina V, Akhmatova F, Chuvarayan G, Arefyev MN, Averkov OV, Volkova AL, Sepkhanyan MS, Vecherko VI, Meray I, Babaeva L, Goreva L, Pisaryuk A, Potapov P, Teterina M, Ageev F, Silvestrova G, Fedulaev Y, Pinchuk T, Staroverov I, Kalimullin D, Sukhinina T, Zhukova N, Ryabov V, Kruchinkina E, Vorobeva D, Shevchenko I, Budyak V, Elistratova O, Fetisova E, Islamov R, Ponomareva E, Khalaf H, Shaimaa AA, Kamal W, Alrahimi J, Elshiekh A, Balghith M, Ahmed A, Attia N, Jamiel AA, Potpara T, Marinkovic M, Mihajlovic M, Mujovic N, Kocijancic A, Mijatovic Z, Radovanovic M, Matic D, Milosevic A, Savic L, Subotic I, Uscumlic A, Zlatic N, Antonijevic J, Vesic O, Vucic R, Martinovic SS, Kostic T, Atanaskovic V, Mitic V, Stanojevic D, Petrovic M. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. Eur Heart J Qual Care Clin Outcomes 2022; 9:8-15. [PMID: 36259751 DOI: 10.1093/ehjqcco/qcac067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 10/11/2022] [Indexed: 11/12/2022]
Abstract
AIMS The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. METHODS AND RESULTS Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. CONCLUSION The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.
Collapse
Affiliation(s)
- Ramesh Nadarajah
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | - Peter Ludman
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Yolande Appelman
- Department of Cardiology, Amsterdam UMC-Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Salvatore Brugaletta
- Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Andrzej Budaj
- Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
| | - Hector Bueno
- Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - Kurt Huber
- 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Vienna, Austria.,Medical Faculty, Sigmund Freud University, Vienna, Austria
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.,Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Sergio Leonardi
- University of Pavia, Pavia, Italy.,Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
| | - Maddalena Lettino
- Cardio-Thoracic and Vascular Department, San Gerardo Hospital, ASST-Monza, Monza, Italy
| | - Dejan Milasinovic
- Department of Cardiology, University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Chris P Gale
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ding WY, Proietti M, Romiti GF, Vitolo M, Fawzy AM, Boriani G, Marin F, Blomstrom-Lundqvist C, Potpara TS, Fauchier L, Lip GYH. Impact of ABC pathway adherence in high-risk patients with atrial fibrillation: an analysis from the ESC-EHRA EORP-AF long-term general registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The impact of Atrial Fibrillation Better Care (ABC) pathway adherence among high-risk subgroups of patients with atrial fibrillation (AF), ie. those with chronic kidney disease (CKD), advanced age and/or prior thromboembolism remains unknown. We evaluated the impact of ABC pathway adherence on clinical outcomes in these high-risk AF patients.
Methods
The EORP-AF General Long-Term Registry is a prospective, observational registry from 250 centres across 27 European countries. High-risk patients were defined as those with either CKD (eGFR <60 mL/min/1.73 m2), older age (≥75 years) and/or prior thromboembolism. The primary outcome was a composite event of all-cause death, any thromboembolism and acute coronary syndrome, evaluated according to ABC pathway adherence.
Results
A total of 6646 patients with AF were included (median age was 70 [IQR 61–77] years; 40.2% females). There were 3304 (54.2%) `high risk' patients with either CKD (n=1750), older age (n=2236) or prior thromboembolism (n=728). Among these there were 924 (28.0%) managed as adherent to ABC.
At 2-year follow-up, a total of 966 (14.5%) patients reported the primary outcome. The incidence of the primary outcome was significantly lower in high-risk patients managed as adherent to ABC pathway (IRR 0.53 [95% CI, 0.43–0.64]). Consistent results were obtained in the individual subgroups [Table]. Using multivariable Cox proportional hazards analysis, ABC adherence in the high-risk cohort was independently associated with a lower risk of primary outcome (aHR 0.64 [95% CI, 0.51–0.80]), as well as in the CKD (aHR 0.51 [95% CI, 0.37–0.70]) and elderly subgroups (aHR 0.69 [95% CI, 0.53–0.90]). Overall, there was greater reduction in the risk of primary outcome as more ABC criteria were fulfilled, both in the overall high-risk patients, as well as in the individual subgroups [Figure].
Conclusion
In a large, contemporary European AF cohort there was a significant proportion of high-risk patients. Among these, a low prevalence of integrated care, as assessed by adherence to ABC pathway, was found. Nonetheless, a clinical management adherent to the ABC pathway was associated with a significant reduction in the risk of adverse outcomes, the benefits of which were more significant with increasing number of ABC criteria adherent.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- W Y Ding
- University of Liverpool , Liverpool , United Kingdom
| | | | | | - M Vitolo
- University of Liverpool , Liverpool , United Kingdom
| | - A M Fawzy
- University of Liverpool , Liverpool , United Kingdom
| | - G Boriani
- Modena Polyclinic Modena University Hospital , Modena , Italy
| | - F Marin
- University of Murcia , Murcia , Spain
| | | | | | - L Fauchier
- University Hospital of Tours , Tours , France
| | - G Y H Lip
- University of Liverpool , Liverpool , United Kingdom
| |
Collapse
|
6
|
Escolar Conesa A, Esteve Pastor MA, Roldan Schilling V, Rivera Caravaca JM, Gil Perez P, Gonzalez Lozano E, Taboada Martin R, Arribas Leal JM, De La Morena Valenzuela G, Saura Espin D, Oliva Sandoval MJ, Pinar Bermudez E, Garcia De Lara J, Marin F. Clinical and prognosis assessment of Atrial Fibrillation patients with significant valvular disease. Validation of the EHRA valve classification (Evaluated Heartvalves. Rheumatic or Artificial). Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Historically, the definition of valvular heart disease in atrial fibrillation (AF) patients has been inconsistent. For this reason, in 2017 the EHRA proposed a more accurate classification, classifing AF patients in EHRA I (AF patients with mechanical prostheses or moderate/severe rheumatic mitral stenosis), EHRA II (includes the presence of significant valve disease, bioprosthetic valve replacement, TAVR – Transcatheter Aortic Valve Replacement – or mitraclip) and EHRA III (absence of valve involvement).
Purpose
The objective was to evaluate the prevalence of valve involvement in AF patients, clinical characteristics and adverse outcomes according to new EHRA classification, focusing in the EHRA II vs EHRA III comparison.
Methods
Observational, multicenter, retrospective study of stable anticoagulated AF patients was performed. Clinical, echocardiographic, demographic characteristics and adverse events after 2 years of follow-up were collected according to EHRA II vs EHRA III groups.
Results
981 patients were analyzed: 755 (76.9%) classified as EHRA II [440 (56.8%) with native valve involvement, 134 (17.8%) with surgical biological prostheses and 181 (23.4%) with TAVR] and 226 (23.1%) as EHRAIII. Higher comorbidity profile was observed in the different EHRA II subgroups compared to patients with EHRA III (Table 1). After 2 years of follow-up, the occurrence of adverse events was higher in EHRA-II than EHRA III patients (Figure 1). In the Cox analysis, weo bserved that patients with native valve involvement and TAVR had up to 3 times higher risk of mortality [HR 3.32, (95% CI 1.88–5.85; p<0.001)], 2 times higher risk of Heart Failure [HR 2.14, (95 CI 1.30–3.5; p<0.001)] and MACE [HR 2.01, (95% CI 1.14–3.52; p<0.015)] than EHRA III patients.
Conclusion
The prevalence of valve involvement in patients with AF is high. Only 23% of AF patients did not present any valve disease. Patients with native valve involvement or TAVR had a high burden of comorbidities and cardiovascular risk factors. Patients with native involvement and TAVR also showed an 2.5-fold increased risk of adverse events during the follow-up. These findings highlight the increased risk related with the presence of valve disease in patients with AF.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Escolar Conesa
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - M A Esteve Pastor
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - V Roldan Schilling
- Morales Meseguer University General Hospital, Hematology , Murcia , Spain
| | - J M Rivera Caravaca
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - P Gil Perez
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - E Gonzalez Lozano
- Virgen of the Arrixaca University Clinical Hospital, Clinical Pharmacology , El Palmar , Spain
| | - R Taboada Martin
- Virgen of the Arrixaca University Clinical Hospital, Cardiac Surgery , El Palmar , Spain
| | - J M Arribas Leal
- Virgen of the Arrixaca University Clinical Hospital, Cardiac Surgery , El Palmar , Spain
| | | | - D Saura Espin
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - M J Oliva Sandoval
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - E Pinar Bermudez
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - J Garcia De Lara
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| | - F Marin
- Virgen of the Arrixaca University Clinical Hospital, Cardiology , El Palmar , Spain
| |
Collapse
|
7
|
Bonini N, Proietti M, Romiti GF, Vitolo M, Fawzy AM, Ding WY, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani GA, Lip GYH. ABC adherence and impact of optimal medical therapy in heart failure patients with atrial fibrillation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure (HF) has close association with atrial fibrillation (AF). The ESC guideline recommended Atrial fibrillation Better care (ABC) pathway aims to reduce major cardiovascular adverse outcomes with an integrated care approach. Optimal medical treatment (OMT) represents the cornerstone in HF management.
Purpose
To investigate the variables affecting OMT treatment and its impact, in conjunction with ABC pathway adherence (vs non-adherence, ie.no ABC), in a large contemporary cohort of European AF patients with HF enrolled in the ESC-EHRA EORP-AF General Long-Term Registry.
Methods
OMT was defined as treatment with Angiotensin-converting-enzyme inhibitors (ACE-i)/ Angiotensin receptor blockers (ARBs) with Beta-Blockers and/or Mineralocorticoid receptor antagonists (MRAs), and compared to non-OMT adherence (“no OMT”). A logistic regression analysis explored factors associated with OMT adherence. We identified three patient groups: (i) HF with no OMT/no ABC; (ii) HF with OMT/no ABC; (iii) HF with OMT/ABC. Primary outcome was a composite outcome of all-cause death and major adverse cardiac events (MACE).
Results
Among the original 11096 patients enrolled, 9857 (88.8%) were included in this analysis. Among these, 3819 (38.7%) had HF. Compared to non HF patients, those with HF were older, more likely female, had more comorbidities and higher thromboembolic risk. OMT prevalence was 2228/3819 (58.3%), while ABC adherence was 23.3%.
On logistic multivariable regression, increasing age, higher BMI and higher frailty index were associated with OMT adherence, while male sex, anemia, renal disease and EHRA II–IV were inversely associated with OMT adherence. According to three HF groups, the rates of composite outcome progressively decreased (HF with no OMT/no ABC 26.4%; HF with OMT/no ABC 24%, HF with OMT/ABC 19%; p<0.001). Kaplan Meier curve showed progressively lower cumulative risk for the composite outcome across the three groups with the lowest risk among HF patients with OMT/ABC (Log-rank: p=0.002) [Figure 1]. Adjusted Cox regression analysis showed that when compared to HF with no OMT/no ABC group, there was a progressively lower risk with OMT and/or ABC adherence (HF with OMT/no ABC: HR 0.81 [95% CI, 0.64–1.02]; HF with OMT/ABC: HR 0.68 [95% CI, 0.5–0.92]).
Conclusions
After two years of follow-up, in a large contemporary cohort of European AF patients with HF, OMT adherence was suboptimal, being influenced by several clinical factors, determining a low adherence to the ABC pathway. OMT alone showed a non-significant reduction in composite outcome events. Conversely HF patients managed with OMT in the context of ABC pathway adherence showed the best reduction in risk of adverse outcomes.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022). - I agree that this information can be anonymised and then used for statistical purposes only
Collapse
Affiliation(s)
- N Bonini
- University of Liverpool , Liverpool , United Kingdom
| | | | - G F Romiti
- Sapienza University of Rome , Rome , Italy
| | - M Vitolo
- University of Modena and Reggio Emilia , Modena , Italy
| | - A M Fawzy
- University of Liverpool , Liverpool , United Kingdom
| | - W Y Ding
- University of Liverpool , Liverpool , United Kingdom
| | - L Fauchier
- University Hospital of Tours , Tours , France
| | - F Marin
- Virgen of the Arrixaca University Hospital , Murcia , Spain
| | - M Nabauer
- Ludwig Maximilians University , Munich , Germany
| | | | - G A Dan
- University of Bucharest Carol Davila , Bucharest , Romania
| | - G A Boriani
- University of Modena and Reggio Emilia , Modena , Italy
| | - G Y H Lip
- University of Liverpool , Liverpool , United Kingdom
| |
Collapse
|
8
|
Proietti M, Romiti GF, Vitolo M, Bonini N, Fawzy AM, Ding WY, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH. Features of clinical complexity in european patients with atrial fibrillation: a report from the ESC-EHRA EORP atrial fibrillation general long-term registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
There is increasing concern regarding the burden of clinical complexity, beyond thromboembolic risk, in patients with atrial fibrillation (AF). Also, clinical complexity is heterogenous and entails differential impact on the patients' clinical course.
Purpose
To explore different complexity features in AF patients in determining differences in clinical management and outcomes.
Methods
We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Features of complexity were analysed in the context of the following high-risk groups: i) only CHA2DS2-VASc ≥2; ii) history of stroke/bleeding; iii) chronic kidney disease (creatinine clearance <60 mL/min, CKD); iv) frail (frailty index ≥0.25); v) ≥2 criteria. All these groups were compared to a low-risk group (CHA2DS2-VASc 0–1). We examined use of oral anticoagulant (OAC) and the risks of a composite outcome of all-cause death and major adverse cardiovascular events.
Results
A total of 10285 patients (mean [SD] age 68.8 [11.5] years, 4107 [39.9%] females) were included in the analysis. Of these, 3944 (38.3%) had only CHA2DS2-VASc ≥2; 412 (4.0%); history of stroke/bleeding; 1480 (14.4%) CKD; 1007 (9.8%) were frail; 1315 (12.8%) had ≥2 criteria; and 2127 (20.7%) were low-risk. After adjustment for age, sex, type of AF and EHRA score, compared to low-risk patients, all the other groups were associated with OAC prescription but with progressively lower odds ratio, while those ≥2 criteria which were least likely prescribed with OAC (Table 1).
After a mean (SD) 634.5 (223.0) days of follow-up, a total of 1432 events were recorded. After adjustment for confounders, Cox regression analysis found that all the complexity groups were associated with a higher risk of the composite outcome across the groups (Figure 1). In patients with available data about ABC (Atrial fibrillation Better Care) pathway adherence, the latter adherence was associated a significant incidence rate reduction (IRR) compared to non-ABC adherence in those with ≥2 criteria of clinical complexity (IRR 0.46, 95% CI 0.30–0.71), and in the CKD complexity group (IRR 0.57, 95% CI 0.41–0.81).
Conclusions
In a large contemporary cohort of European AF patients, features of clinical complexity affect differently prescriptions of OAC. All the subgroups of clinical complexity were associated with a higher risk of adverse outcomes, which were reduced by adherence to ABC pathway.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and PfizerAlliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022).
Collapse
Affiliation(s)
- M Proietti
- University of Milan, Department of Clinical Sciences and Community Health , Milan , Italy
| | - G F Romiti
- Sapienza University of Rome, Department of Translational and Precision Medicine , Rome , Italy
| | - M Vitolo
- University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - N Bonini
- University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - A M Fawzy
- University of Liverpool, Liverpool Centre for Cardiovascular Sciences , Liverpool , United Kingdom
| | - W Y Ding
- University of Liverpool, Liverpool Centre for Cardiovascular Sciences , Liverpool , United Kingdom
| | - L Fauchier
- University Hospital of Tours , Tours , France
| | - F Marin
- University of Murcia , Murcia , Spain
| | - M Nabauer
- Ludwig-Maximilians University , Munich , Germany
| | | | - G A Dan
- University of Medicine and Pharmacy Carol Davila , Bucharest , Romania
| | - G Boriani
- University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - G Y H Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Sciences , Liverpool , United Kingdom
| |
Collapse
|
9
|
Rivera-Caravaca JM, Serna MJ, Lopez-Galvez R, Lip GYH, Marin F, Roldan V. Longitudinal changes in CHA2DS2-VASc and HAS-BLED scores are superior to baseline score values for predicting ischemic stroke and major bleeding in atrial fibrillation patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Stroke and bleeding risks in atrial fibrillation (AF) are often assessed at baseline, as a “one-off” evaluation. However, these baseline values are usually applied to predict outcomes many years later, and therefore lack the consideration that the risk is not static.
Purpose
Our aim was to investigate if dynamic changes of CHA2DS2-VASc and HAS-BLED over time have an effect on the prediction of stroke and bleeding risks.
Methods
We included AF patients who were stable while taking vitamin K antagonists (INR 2.0–3.0) for 6 months attending a tertiary hospital (May 2007-December 2007). During 6-years of follow-up, ischemic strokes/transient ischemic attacks (TIAs), major bleeds, and all-cause deaths were recorded. CHA2DS2-VASc and HAS-BLED were recalculated every 2-years, and their predictive abilities were tested for outcomes in periods of 2-years (from year 0 to 2, year 2 to 4 and year 4 to 6).
Results
1361 patients (693 [50.9%] females, median age 76 [IQR 71–81] years, mean CHA2DS2-VASc and HAS-BLED of 4.0±1.7 and 2.9±1.2, respectively) were included. The predictive ability for ischemic stroke/TIA of the baseline CHA2DS2-VASc for 2-years events was 0.662 (0.637–0.688, p<0.001). Compared to the baseline CHA2DS2-VASc, the CHA2DS2-VASc re-calculated at 2-years presented significantly higher predictive ability for ischemic stroke/TIA during the period 2–4 years (c-indexes: 0.701 [0.675–0.727] vs. 0.604 [0.576–0.631], p<0.001). Integrated discrimination improvement (IDI) and net reclassification improvement (NRI) showed an improvement in sensitivity of 0.014 (p<0.001) and a better reclassification (0.677, p<0.001). Similarly, the CHA2DS2-VASc re-calculated at 4-years yielded significantly better predictive performance for ischemic stroke/TIA during the period 4–6 years in comparison to the baseline CHA2DS2-VASc (c-indexes: 0.761 [0.734–0.786] vs. 0.682 [0.653–0.710], p=0.026). Again, IDI reported an improvement (IDI = 0.030, p<0.001) and there was an important enhance of the reclassification ability (NRI = 0.757, p<0.001).
The c-index of the baseline HAS-BLED for events at 2-years was 0.744 (0.720–0.767, p<0.001). At 2-years, the re-calculated HAS-BLED score showed higher predictive ability compared to the baseline HAS-BLED during the period 2–4 year (c-indexes: 0.709 [0.680–0.738] vs. 0.663 [0.632–0.693], p=0.003). Accordingly, IDI and NRI demonstrated significant improvements for the re-calculated HAS-BLED compared to baseline (IDI = 0.016, p=0.001; NRI = 0.444, p<0.001). For major bleeding during the period 4–6 years, the c-index of the HAS-BLED score re-calculated at 4-years was non-significantly different to baseline HAS-BLED at baseline (0.631 [0.601–0.660] vs. 0.623 [0.593–0.652], p=0.751), although showed a slight enhance in sensitivity (IDI = 0.009, p=0.018).
Conclusions
In AF patients, stroke and bleeding risks are dynamic and change over time. The CHA2DS2-VASc and HAS-BLED scores should be regularly reassessed.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This work was supported by the Spanish Ministry of Economy, Industry, and Competitiveness, through the Instituto de Salud Carlos III after independent peer review (research grant: PI17/01375 co-financed by the European Regional Development Fund)
Collapse
Affiliation(s)
- J M Rivera-Caravaca
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - M J Serna
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| | - R Lopez-Galvez
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - G Y H Lip
- Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool Center for Cardiovascular Siences , Liverpool , United Kingdom
| | - F Marin
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - V Roldan
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| |
Collapse
|
10
|
Romiti GF, Proietti M, Vitolo M, Bonini N, Fawzy AM, Ding WY, Fauchier L, Marin F, Nabauer M, Dan GA, Potpara T, Boriani G, Lip GYH. Impact of the atrial fibrillation better care pathway in clinically complex patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Clinical complexity is increasingly prevalent among patients with atrial fibrillation (AF). The “Atrial fibrillation Better Care” (ABC) pathway approach has been proposed to streamline a more holistic and integrated approach to AF care; however, there are limited data on its usefulness among clinically complex patients. We analyzed the impact of the ABC pathway in a contemporary cohort of clinically complex AF patients.
Methods
From the ESC-EHRA EORP-AF General Long-Term Registry, we analyzed clinically complex AF patients, defined as the presence of frailty (according to a 40-items Frailty Index), multimorbidity and/or polypharmacy. A K-medoids cluster analysis was performed to identify different groups of clinical complexity. The impact of an ABC-adherent approach on the risk of all-cause death, major adverse cardiovascular events (MACEs) and the composite outcome of all-cause death and MACE was analyzed through Cox-regression analyses, and delay of event (DoE) analyses; number needed to treat (NNT) was also estimated at 1 year of follow-up.
Results
Among 9,966 AF patients, 8,289 (92.3%) were clinically complex. Risk of all outcomes was higher among clinically complex patient. Adherence to the ABC pathway in the clinically complex group reduced the risk of all-cause death (adjusted HR [aHR]: 0.71, 95% CI 0.57–0.89), major adverse cardiovascular events (MACEs, aHR: 0.68, 95% CI 0.53–0.87) and composite outcome (aHR: 0.69, 95% CI: 0.57–0.84). Using cluster analysis, we identified a high clinical complexity group of AF patients. Adherence to the ABC pathway was associated with a significant reduction in the risk of death (aHR: 0.73, 95% CI 0.55–0.96) and composite outcome (aHR: 0.69, 95% CI 0.57–0.84) in the high-complexity cluster; similar trends were observed for MACEs. In DoE analyses, an ABC-adherent approach resulted in significant gains in event-free survival for all-cause death (Figure 1), MACEs, and composite outcome in clinically complex patients. Based on absolute risk reduction at 1 year of follow-up, the NNTs for ABC pathway adherence was 24 for all-cause death, 31 for MACEs and 20 for the composite outcome.
Conclusions
An ABC-adherent approach reduces the risk of major outcomes in clinically complex AF patients. Ensuring adherence to the ABC pathway is essential to improve clinical outcomes amongst clinically complex AF patients.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Since the start of EORP, several companies have supported the programme with unrestricted grants.
Collapse
Affiliation(s)
- G F Romiti
- University of Liverpool , Liverpool , United Kingdom
| | - M Proietti
- University of Milan, Department of Clinical Sciences and Community Health , Milan , Italy
| | - M Vitolo
- University of Modena and Reggio Emilia, Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - N Bonini
- University of Modena and Reggio Emilia, Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - A M Fawzy
- University of Liverpool , Liverpool , United Kingdom
| | - W Y Ding
- University of Liverpool , Liverpool , United Kingdom
| | - L Fauchier
- Centre Hospitalier Universitaire Trousseau, Service de Cardiologie , Tours , France
| | - F Marin
- Virgen de la Arrixaca University Clinical Hospital, Department of Cardiology , Murcia , Spain
| | - M Nabauer
- Ludwig-Maximilians University, Department of Cardiology , Munich , Germany
| | - G A Dan
- Colentina University Hospital, University of Medicine “Carol Davila” , Bucharest , Romania
| | - T Potpara
- School of Medicine, Belgrade University , Belgrade , Serbia
| | - G Boriani
- University of Modena and Reggio Emilia, Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences , Modena , Italy
| | - G Y H Lip
- University of Liverpool , Liverpool , United Kingdom
| |
Collapse
|
11
|
Vitolo M, Proietti M, Bonini N, Romiti GF, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH, Boriani G. Factors associated with progression of atrial fibrillation and impact on all-cause mortality: an ancillary analysis from the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation General. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Paroxysmal atrial fibrillation (AF) often shows a natural progression towards more sustained forms of the arrhythmia. Real-world data on clinical factors associated to AF progression and its impact on long-term outcome are limited.
Purpose
To investigate the factors associated with progression of AF and its impact on all-cause mortality in a contemporary cohort of European AF patients
Methods
We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. Patients with paroxysmal AF at baseline or first detected AF who underwent successful cardioversion were included. Patients with known rhythm status at 1-year were then stratified into two groups: (i) No AF progression and (ii) AF progression (as defined by transition to persistent or permanent AF). All-cause mortality at 2-year of follow-up was the primary outcome of the analysis.
Results
A total of 2688 patients were included (median age 67 years, interquartile range [IQR] 60–75, females 44.7%, CHA2DS2VASc score median 3 [1–4], HASBLED median 1 [1–2]). After 1-year of follow-up 2094 (77.9%) patients showed no AF progression while 594 (22.1%) developed AF progression. On multivariable logistic regression analysis, no physical activity (odds ratio [OR] 1.35, 95% confidence interval [CI] 1.02–1.78), valvular heart disease (OR 1.63, 95% CI 1.23–2.15), left atrium diameter (OR 1.03, 95% CI 1.01–1.05) and left ventricular ejection fraction (OR 0.98, 95% CI 0.97–1.00) were independently associated with AF progression at 1-year. At the end of 2-year of follow-up, death occurred in 80/2621 (3.1%) patients. Kaplan-Meier analysis showed a lower cumulative survival from all-cause mortality in patients with AF progression compared to non-progression AF patients (Log Rank p=0.01, Figure 1). On multivariable Cox regression analysis, adjusted for age, sex, heart failure, coronary artery disease, hypertensions, diabetes mellitus, previous thromboembolic events, peripheral artery disease, chronic kidney disease and use of oral anticoagulants, patients with AF progression had an independently higher risk for all-cause mortality (adjusted hazard ratio [aHR] 1.77, 95% CI 1.09–2.89).
Conclusions
In a contemporary cohort of European AF patients, a substantial number of patients progressed to sustained AF within 1 year. Clinical factors related to atrial structural remodeling were independently associated with arrhythmia progression. AF progression was associated with an increased risk of all-cause mortality.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022).
Collapse
Affiliation(s)
- M Vitolo
- Modena Polyclinic Modena University Hospital , Modena , Italy
| | - M Proietti
- University of Milan, Department of Clinical Sciences and Community Health , Milan , Italy
| | - N Bonini
- Modena Polyclinic Modena University Hospital , Modena , Italy
| | - G F Romiti
- Sapienza University of Rome , Rome , Italy
| | - L Fauchier
- University Hospital of Tours , Tours , France
| | - F Marin
- University of Murcia , Murcia , Spain
| | - M Nabauer
- Ludwig Maximilians University , Munich , Germany
| | - T S Potpara
- University Belgrade Medical School , Belgrade , Serbia
| | - G A Dan
- University of Bucharest , Bucharest , Romania
| | - Z Kalarus
- Silesian Center for Heart Diseases (SCHD) , Zabrze , Poland
| | - L Tavazzi
- Maria Cecilia Hospital , Cotignola , Italy
| | | | - D A Lane
- University of Liverpool, Liverpool Centre for Cardiovascular Science , Liverpool , United Kingdom
| | - G Y H Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science , Liverpool , United Kingdom
| | - G Boriani
- Modena Polyclinic Modena University Hospital , Modena , Italy
| |
Collapse
|
12
|
Bonini N, Proietti M, Romiti GF, Vitolo M, Fawzy AM, Ding YD, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH. Heart failure and cardiovascular outcomes in european patients with atrial fibrillation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Heart failure (HF) has an intimate bidirectional association with atrial fibrillation (AF). Few data are available about the impact of HF phenotypes (HF with preserved ejection fraction, HFpEF; HF with mildly reduced ejection fraction, HFmrEF; HF with reduced ejection fraction, HFrEF) as predictors for adverse outcomes in AF patients.
Purpose
To investigate the association of HFpEF, HFmrEF and HFrEF with adverse outcomes in a large contemporary cohort of European AF patients and evaluate the effect of EF throughout its entire spectrum.
Methods
We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. HF patients were categorized according the three phenotypes and compared to those without HF (“non HF”). Main outcome was a composite outcome of all-cause death and major adverse cardiac events (MACE).
Results
Among the original 11,096 AF patients enrolled, 9857 (88.8%) were included in this analysis (median age 71 years, interquartile range [IQR 63–77], 40.1% females) with median EF 55% [IQR 45–61%] and CHA2DS2-VASc 3 [2–4]). In this cohort, 5935 (60.2%) were non HF patients, and 3240 (32.9%) had HF patients (with HF status and EF values data available). Accordingly, 1662 (51.2%) were categorized as HFpEF; 523 (14.1%) were HFmrEF; and 1235 (35.1%) were HFrEF.
After a median follow-up of 731 days [IQR 690–748], the composite outcome was significantly higher throughout HF categories (HFpEF 19.0%, HFmrEF 21.8% and HFrEF 29.6%, compared to non HF 10.7%; p<0.001). In a fully adjusted multivariate Cox regression, HF phenotypes were associated with a progressively higher risk for the composite outcome (HFpEF HR 1.45 [95% CI, 1.23–1.70]; HFmrEF HR 1.82 [95% CI, 1.45–2.3]; HFrEF HR 2.51 [95% CI, 2.14–2.95], when compared to non HF patients). Considering EF in its continuous spectrum, an adjusted regression curve analysis found that progressively lower EF was associated with a progressively higher risk for the composite outcome, both in HF and overall AF patients (Figure 1, left and right panel, respectively).
Conclusions
Over a two-years follow-up, in a large contemporary cohort of European AF patients, HF phenotypes were associated with a progressively higher risk for adverse outcomes. Lower EF values increased the risk of adverse outcomes both in HF patients and overall AF patients, irrespective of HF phenotype status.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022).
Collapse
Affiliation(s)
- N Bonini
- University of Liverpool , Liverpool , United Kingdom
| | | | - G F Romiti
- Sapienza University of Rome , Rome , Italy
| | - M Vitolo
- University of Modena and Reggio Emilia , Modena , Italy
| | - A M Fawzy
- University of Liverpool , Liverpool , United Kingdom
| | - Y D Ding
- University of Liverpool , Liverpool , United Kingdom
| | - L Fauchier
- University Hospital of Tours , Tours , France
| | - F Marin
- Virgen de la Arrixaca University Clinical Hospital , Murcia , Spain
| | - M Nabauer
- Ludwig Maximilians University , Munich , Germany
| | | | - G A Dan
- University of Bucharest Carol Davila , Bucharest , Romania
| | - G Boriani
- University of Modena and Reggio Emilia , Modena , Italy
| | - G Y H Lip
- University of Liverpool , Liverpool , United Kingdom
| |
Collapse
|
13
|
Rivera-Caravaca JM, Zazo-Luengo B, Martinez-Montesinos L, Lopez-Galvez R, Garcia-Tomas L, Lip GYH, Marin F, Roldan V. Multimorbidity, frailty and malnutrition: moving beyond traditional risk factors for risk assessment in atrial fibrillation. The Murcia Atrial Fibrillation Project II. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The management of atrial fibrillation (AF) has evolved over the last decade with a more towards a more multidisciplinary, integrated and holistic approach. However, several conditions that may influence the prognosis and management of AF patients are still under-recognised.
Purpose
Our aim was to investigate if multimorbidity, frailty and malnutrition are associated with the risk of worse clinical outcomes in patients with recent diagnosis of AF starting oral anticoagulation (OAC) therapy.
Methods
Prospective cohort study including outpatients newly diagnosed with AF starting vitamin K antagonist (VKA) therapy from July 1, 2016 to June 30, 2018. Morbidity was assessed with the crude number of comorbidities. Frailty was assessed with the Clinical Frailty Scale (CFS). Nutrition status was assessed with the Controlling Nutritional Status (CONUT) score. During 2-years of follow-up, we recorded all ischemic strokes/transient ischemic attacks (TIAs), major bleeds (according to the 2005 International Society on Thrombosis and Haemostasis criteria), and all-cause deaths.
Results
We included 1050 patients (540 [51.4%] females, median age 77 [IQR 70–83] years), with median CHA2DS2-VASc of 4 [IQR 3–5] and median HAS-BLED of 2 [IQR 2–3]. The median crude number of comorbidities was 3 [IQR 2–5], whereas the median CFS and CONUT score were 2 [IQR 2–3] and 2 [IQR 1–3], respectively. The crude number of comorbidities, CFS and CONUT score demonstrated a significant positive correlation (p<0.001 for all correlations). After adjusting for several risk factors (age, sex, hypertension, diabetes, previous stroke, vascular disease, heart failure, chronic kidney disease, dyslipidemia, sleep apnoea, hepatic disease, and cancer), the CFS was independently associated with major bleeding (adjusted HR 1.25, 95% CI 1.07–1.45) and all-cause mortality (aHR 1.20, 95% CI 1.09–1.32). The crude number of comorbidities (aHR 1.30, 95% CI 1.14–1.49) was also associated with major bleeding, and the CONUT score (aHR 1.25, 95% CI 1.15–1.35) was associated with all-cause mortality. Any frailty degree (i.e CFS ≥5) was associated with a 3-fold higher risk of major bleeding (aHR 3.04, 95% CI 1.67–5.52) and a 2-fold higher risk of death (aHR 2.04, 95% CI 1.39–3.01), whereas the moderate/severe malnutrition (i.e. CONUT ≥5) was an independent risk factor for ischemic stroke/TIA and (aHR 2.25, 95% CI 1.11–4.56) and death (aHR 3.21, 95% CI 2.14–4.83) (Figures 1 and 2).
Conclusions
Frailty and malnutrition are important risk factors for bleeding, stroke and mortality in AF. The frailty degree and nutritional status should be assessed in all AF patients in order to address them properly and provide a truly integrated management.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This work was supported by the Spanish Ministry of Economy, Industry, and Competitiveness, through the Instituto de Salud Carlos III after independent peer review (research grant: PI17/01375 co-financed by the European Regional Development Fund)
Collapse
Affiliation(s)
- J M Rivera-Caravaca
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - B Zazo-Luengo
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| | - L Martinez-Montesinos
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| | - R Lopez-Galvez
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - L Garcia-Tomas
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| | - G Y H Lip
- Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool Center for Cardiovascular Siences , Liverpool , United Kingdom
| | - F Marin
- Virgen de la Arrixaca University Clinical Hospital, University of Murcia , Murcia , Spain
| | - V Roldan
- Morales Meseguer University General Hospital, Hematology and Clinical Oncology , Murcia , Spain
| |
Collapse
|
14
|
Anguita Gamez M, Esteban A, Bonilla JL, Garcia M, Bernal JL, Del Prado N, Fernandez Perez C, Gomez Doblas JJ, Perez Villacastin J, Marin F, Elola FJ, Anguita Sanchez M. Clinical features and short-term prognosis in the very elderly, >90 year-old, patients hospitalized with heart failure. A population-based study (2016–2019). Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is a main health problem in western countries, and a major cause of hospitalizations and death, particularly in older people. Few data are available about clinical features and prognosis of very old patients, those aged 90 or more years.
Purpose
To analyse the clinical features and short-term prognosis (in-hospital mortality and 30-day readmission rate) of patients aged 90 or more years hospitalized with HF in Spain in the last years.
Methods
We conducted a retrospective analysis of patients discharged with an ICD-10 main diagnosis of HF from the Spanish National Health System (SNHS) public hospitals between 2016 and 2019, using as source of data the Minimum Basic Data Set of the SNHS. A comparison of clinical profile, in-hospital mortality and 30-day cardiovascular readmission rate between patients aged 75 to 89 years and those with 90 or more years was performed.
Results
From 2016 to 2019, 354,792 episodes of people older than 74-year and principal diagnosis of HF were included, being 59.2% female. Mean age of the whole population was 85.2±5.5 years, crude in-hospital mortality rate was 12.7% and crude cardiovascular 30-day readmission rate, 11.8%. The very older patients' subgroup (90 or more year-old) comprised 78.777 patients (22.2%). Table 1 shows the differences in clinical features between these patients and those aged 75 to 89 (77.8%). Patients aged 90 or more years were female in a higher proportion and showed a higher prevalence of cognitive impairment and renal failure, but a lower prevalence of most comorbidities (coronary artery revascularization, valve heart disease, cancer, diabetes mellitus, chronic liver disease). The diagnosis of previous myocardial infarction, stroke and systemic hypertension was similar in both groups (Table 1). Crude 30-day cardiovascular readmission rate was slightly but significantly lower in the oldest subgroup (10.9% vs 12%, p<0.001), while crude in-hospital mortality was higher (18.5% vs 11%, p<0.001).
Conclusions
Patients aged 90 or more years represents almost a fourth part of elderly patients hospitalized with HF in Spain within the last years. In general, prevalence of comorbidities and associated heart disease was similar or lower, but in-hospital mortality was twice higher, as compared with less older patients.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - A Esteban
- University Hospital Severo Ochoa, Cardiology , Leganes , Spain
| | - J L Bonilla
- Hospital San Juan de la Cruz, Cardiology , Ubeda , Spain
| | - M Garcia
- Interhospital Foundation for Cardiovascular Research, Fundacion IMAS , Madrid , Spain
| | - J L Bernal
- Interhospital Foundation for Cardiovascular Research, Fundacion IMAS , Madrid , Spain
| | - N Del Prado
- Interhospital Foundation for Cardiovascular Research, Fundacion IMAS , Madrid , Spain
| | - C Fernandez Perez
- Interhospital Foundation for Cardiovascular Research, Fundacion IMAS , Madrid , Spain
| | - J J Gomez Doblas
- Virgin of Victory University Hospital, Cardiology , Malaga , Spain
| | | | - F Marin
- University Hospital Virgen de la Arrixaca, Cardiology , Murcia , Spain
| | - F J Elola
- Interhospital Foundation for Cardiovascular Research, Fundacion IMAS , Madrid , Spain
| | | |
Collapse
|
15
|
Lopez-Galvez R, Rivera-Caravaca JM, Mandaglio-Collados D, Martinez CM, Carpes M, Lahoz A, Hernandez-Romero D, Orenes-Pinero E, Lopez-Garcia C, Roldan V, Arribas JM, Canovas S, Lip GYH, Marin F. The ideal environment for the development of postcardiac surgery atrial fibrillation: evidence for endothelial activation and poor cell-cell interaction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The development of post-operative atrial fibrillation (POAF) after cardiac surgeryis associated with pre-existing endothelial activation and systemic inflammation due to adhesion and transmigration of leukocytes into the interstitium. The electrical remodelling associated with AF causes changes in connexins, resulting in ineffective electrical coupling between cells and thus ineffective cell-cell communication.There is also an association between the inflammatory state, and the presence of cardiac fibrosis, oxidative stress and myocyte apoptosis.
Purpose
Our aim was to investigate the pathophysiologicaland regulatory mechanisms of AF through endothelial activation and inflammatory status, as well as cell-cell interactions (connexins) in relation to POAF amongst a cohort of patients undergoing cardiac surgery.
Methods
We studied prospective patients who underwent CABG (52.9%) or cardiac valve (47.1%) surgery without previous documented AF. Patients with permanent AF who underwent CABG or cardiac valve surgery were also included as positive controls. Plasma samples were collected at baseline and 24 hours after surgery, to assess the impact of surgery. To detect endothelial activation, vascular cell adhesion protein-1 (VCAM-1 (CD106)) was evaluated by ELISA assay in plasma samples. Expression of connexin 40 and 43 were measured by inmunohistochemistry in atrial tissue samples.
Results
We included 117 patients (75.2% males, median age 67 [IQR 59.5–73.0] years), of whom17 (14.5%) patients had permanent AF; 27 (23.1%) developed POAF and 73 (62.4%) had no AF detected.
We found higher baseline VCAM-1 levels versus 24-hour samples overall (p=0.001). When comparing groups, baseline VCAM-1 levels were higher in patients with permanent AF compared to non-AF (p=0.035); and in permanent AF compared to POAF (p=0.049). VCAM-1 levels at 24h followed the same trends between permanent AF and non-AF (p=0.001), and permanent AF versus POAF (p=0.013) (Table 1). VCAM-1 levels over the third tertile (i.e.>49.77 ng/ml) increased the risk of AF almost 3-fold (OR 2.85, 95% CI 1.06–7.70; p=0.039). There was a significant decrease in the expression of connexion 40 in patients with AF (ie. patients with permanent AF or POAF) compared to non-AF patients (1.00 [0.50–2.31] vs. 2.48 [1.94–3.00], p=0.044), while connexin 43 was non-significantly different (1.07 [0.41–1.75] vs. 2.00 [0.63–2.25], p=0.289) (Table 2).
Conclusions
VCAM-1 levels were upregulated in patients with permanent AF and POAF compared to patients without AF, and remained higher even after surgery, thus demonstrating a relevantendothelial activation. The pro-inflammatory state presented in these patients with AF, along with decreased connexin 40 expression impacting cell-to-cell conduction, suggests a potential combination for atrial remodelling and incident AF.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- R Lopez-Galvez
- Virgin of the Arrixaca University Clinical Hospital, Department of Cardiology, University of Murcia, CIBERCV , Murcia , Spain
| | - J M Rivera-Caravaca
- Virgin of the Arrixaca University Clinical Hospital, Department of Cardiology, University of Murcia, CIBERCV , Murcia , Spain
| | - D Mandaglio-Collados
- Virgin of the Arrixaca University Clinical Hospital, Department of Cardiology, University of Murcia, CIBERCV , Murcia , Spain
| | - C M Martinez
- Virgin of the Arrixaca University Clinical Hospital, Instituto Murciano de Investigaciόn Biosanitaria (IMIB-Arrixaca) , Murcia , Spain
| | - M Carpes
- Virgin of the Arrixaca University Clinical Hospital, Instituto Murciano de Investigaciόn Biosanitaria (IMIB-Arrixaca) , Murcia , Spain
| | - A Lahoz
- Virgin of the Arrixaca University Clinical Hospital, Cardiovascular Surgery Service, Instituto Murciano de Investigaciόn Biosanitaria (IMIB-Arrixaca) , Murcia , Spain
| | - D Hernandez-Romero
- University of Murcia, Departament of Legal and Forensic Medicine , Murcia , Spain
| | - E Orenes-Pinero
- Virgin of the Arrixaca University Clinical Hospital, Proteomic Unit, Instituto Murciano de Investigaciones Biosanitarias (IMIB-Arrixaca) , Murcia , Spain
| | - C Lopez-Garcia
- Virgin of the Arrixaca University Clinical Hospital, Department of Cardiology, University of Murcia, CIBERCV , Murcia , Spain
| | - V Roldan
- University Hospital Morales Meseguer, Department of Hematology and Clinical Oncology, Instituto Murciano de Investigaciόn Biosanitaria , Murcia , Spain
| | - J M Arribas
- Virgin of the Arrixaca University Clinical Hospital, Cardiovascular Surgery Service, Instituto Murciano de Investigaciόn Biosanitaria (IMIB-Arrixaca) , Murcia , Spain
| | - S Canovas
- Virgin of the Arrixaca University Clinical Hospital, Cardiovascular Surgery Service, Instituto Murciano de Investigaciόn Biosanitaria (IMIB-Arrixaca) , Murcia , Spain
| | - G Y H Lip
- Liverpool Heart and Chest Hospital, Liverpool Centre for Cardiovascular Science, University of Liverpool , Liverpool , United Kingdom
| | - F Marin
- Virgin of the Arrixaca University Clinical Hospital, Department of Cardiology, University of Murcia, CIBERCV , Murcia , Spain
| |
Collapse
|
16
|
Esteban Fernandez A, Anguita M, Bonilla JL, Anguita M, Ruesgas R, Molina M, Garcia M, Bernal JL, Del Prado N, Fernandez Perez C, Marin F, Perez Villacastin J, Gomez Doblas JJ, Fernandez Rozas I, Elola FJ. 1-year hospital readmissions due to cardiovascular causes after a heart failure episode in elderly patients in Spain. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The prevalence of heart failure (HF) increases with age, one of the leading causes of hospitalization and death in the elderly. However, there are little data about the long-term readmission rate of elderly patients after an episode of HF admission in Spain.
Purpose
Study 1-year hospital readmissions due to cardiovascular causes in patients ≥75 years discharged to a hospital due to HF in Spain.
Methods
We performed a retrospective analysis of the Minumum basic dataset of Spain, including all episodes of HF discharged from public hospitals in Spain between 2016 and 2019. The codification was made with ICD-10. We selected patients ≥75 years with HF as the principal diagnosis. We analyzed predictors of readmissions 365 days after the index episode of HF hospitalization with Poisson regression.
Results
236,463 index episodes of HF in>75 years were included. 59.1% were female, and the mean age was 85 (SD 5.6) years. 35.0% had HF-pef, 4.3% HF-ref, and 60.7% had unknown LVEF HF.
39.6% of patients had at least one readmission (mean 1.7 readmissions by year for these patients), with no differences in sex or age. Patients with non-cardiovascular comorbidities (renal failure, chronic lung disorders, and severe hematological disorders) as well as coronary atherosclerosis and diabetes were more likely to be readmitted (Table 1).
Conclusions
After a hospital discharge for HF in patients ≥75 years, the crude ratio of readmission due to cardiovascular causes at 1-year was 39.6%. Readmissions were more likely in patients with non-cardiovascular comorbidities, predominantly renal, hematological, and chronic respiratory disorders, and those with diabetes and coronary atherosclerosis.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - M Anguita
- University Hospital Reina Sofia , Cordoba , Spain
| | - J L Bonilla
- Hospital San Juan de la Cruz , Ubeda , Spain
| | - M Anguita
- Hospital Clinico San Carlos , Madrid , Spain
| | - R Ruesgas
- Severo Ochoa Hospital , Leganes , Spain
| | - M Molina
- Severo Ochoa Hospital , Leganes , Spain
| | | | | | | | | | - F Marin
- Virgen of the Arrixaca University Hospital , Murcia , Spain
| | | | | | | | | |
Collapse
|
17
|
Fezzi S, Castaldi G, Widmann M, Marin F, Galli V, Ruzzarin A, Pesarini G, Scarsini R, Pighi M, Tavella D, Ribichini F. Spontaneous, independent, single-center renal denervation registry of a resistant hypertension multidisciplinary team. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Uncontrolled resistant hypertension (URH) is defined as PAS ≥140mmHg despite the adherence to at least 3 maximally tolerated doses of antihypertensive medications. In the adult population URH is a common condition with a prevalence that ranges between 10–15% and is related with poor prognosis and higher risk of major adverse cardiovascular events.
Renal sympathetic denervation (RDN) has recently proved efficacy in different hypertensive subsets of patients. However, patients with chronic kidney disease (CKD) IIIB-V stages (i.e. glomerular filtrate rate <45 ml/min) have been systematically excluded from randomized clinical trials (RCT).
Purpose
To evaluate the safety and the efficacy of RDN in a daily practice population of patients with URH on top of medical therapy, including patients with renal function impairment (GFR<45ml/min).
Methods
Consecutive unselected patients with URH undergoing RDN were enrolled. Indication of RDN was assessed in a multidisciplinary team involving cardiologist, nephrologist and hypertension specialists, after secondary forms of hypertension had been excluded. Efficacy was defined as the inter-individual change of office (OBP) and ambulatory blood pressure monitoring (ABPM) at 3, 6 and 12 months after RDN. Safety as the absence of any device-related major complication (BARC classification), end-stage renal disease, stroke, acute myocardial infarction and any cause of death within 1 month of the procedure. Safety and efficacy profile was assessed in patients with an estimated GFR below 45 ml/min/1.73 m2.
Results
Seventy-two patients underwent RDN for URH from 2012 to 2022. The population presented with multiple comorbidities and target organ damage: almost 50% were smoker, 43% diabetic, 33% PAD, 25% CAD and 60% CKD. Isolated systolic hypertension prevalence was 53%. The average number of antihypertensive medications at baseline was 5.3±1.1. Baseline OBP and ABPM were 158.8/86.6±23.4/15.3 mmHg and 151.4/87.6±18.8/14.2 mmHg, respectively. The vast majority of the procedures were performed with tetrapolar radio-frequency catheter (91.7%), with 37.3±14.3 number of ablations per procedure. The average amount of contrast medium was 72.1±38.1 ml. At 12-month follow-up a significant reduction of office and ambulatory systolic BP, respectively by −15.66±29.73 mmHg (P<0.01) and by −11.3±23.1mmHg (P<0.05), was noticed. BP reduction at 12-month follow-up among patients with eGFR <45 ml/min was similar to that obtained in patients with higher eGFR. No major complications were observed and renal function was stable up to 12 months, even in patients with lowest eGFR at baseline.
Conclusion(s)
RDN is safe and feasible in patients with URH on top of medical therapy, even in a high-risk CKD population with multiple comorbidities. Our experience underlines the central role of multidisciplinary team evaluation for the targeted management of uncontrolled resistant hypertension.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Fezzi
- Integrated University Hospital of Verona , Verona , Italy
| | - G Castaldi
- Integrated University Hospital of Verona , Verona , Italy
| | - M Widmann
- Integrated University Hospital of Verona , Verona , Italy
| | - F Marin
- Integrated University Hospital of Verona , Verona , Italy
| | - V Galli
- Integrated University Hospital of Verona , Verona , Italy
| | - A Ruzzarin
- Integrated University Hospital of Verona , Verona , Italy
| | - G Pesarini
- Integrated University Hospital of Verona , Verona , Italy
| | - R Scarsini
- Integrated University Hospital of Verona , Verona , Italy
| | - M Pighi
- Integrated University Hospital of Verona , Verona , Italy
| | - D Tavella
- Integrated University Hospital of Verona , Verona , Italy
| | - F Ribichini
- Integrated University Hospital of Verona , Verona , Italy
| |
Collapse
|
18
|
Esteve Pastor M, Marin F, Anguita M, Sanmartin M, Rafols C, Arribas Ynsaurriaga F, Baron Esquivas G, Barrios V, Cosin Sales J, Freixa Pamias R, Perez Cabeza A, Vazquez Rodriguez JM, Lekuona Goya I. 2MACE score predicts cardiovascular adverse events in real-world atrial fibrillation patients under rivaroxaban therapy. Data from EMIR study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial Fibrillation (AF) patients have higher risk of major adverse cardiovascular events (MACEs). In 2015, the 2MACE score (2 points for metabolic syndrome and age ≥75, and 1 point for myocardial infarction [MI] or revascularization, congestive heart failure [ejection fraction ≤40%] and thromboembolism [stroke or transient ischemic attack]) was described to stratify cardiovascular risk and 2MACE≥3 was related with high risk of MACE in AF patients but a long-term validation in prospective patients under direct anticoagulants has not been performed yet.
The aim of this study was to analyse the incidence of cardiovascular events and to validate the 2MACE score as predictor of MACEs.
Methods
EMIR study [acronym from 'Estudio observacional para la identificaciόn de los factores de riesgo asociados a eventos cardiovasculares Mayores en pacientes con fIbrilaciόn auricular no valvular tratados con un anticoagulante oral directo (Rivaroxaban)'] was an observational, multicenter, post-authorization and prospective study that involved AF patients under oral anticoagulation with rivaroxaban at least 6 months before enrolment. We analyzed baseline clinical characteristics and adverse events after 2.5 years of follow up: annual incidence of thromboembolic events, MACE (composite of nonfatal MI, coronary revascularization and cardiac death) and cardiovascular mortality were analyzed.
Results
We analyzed 1,433 patients (55.5% women, mean 74.2±9.7 years). 385 (26.9%) patients had 2MACE score ≥3 and of those high-risk patients, 42.1% had previous coronary disease, 12.5% had previous peripheral artery disease, 40.7% had diabetes mellitus, 39% heart failure and 50% had chronic kidney disease (GFR<60 ml/min). After 2.5 (2.2–2.6) years of follow-up, we observed patients with 2MACE score ≥3 had higher rate of adverse events (Table), specially of higher rate of cardiovascular mortality and MACE. Patients with 2MACE score ≥3 had RR 4.09 (2.59–6.45; p<0.001) for MACE. Indeed, patients with 2MACE score ≥3 had around 6-fold risk of cardiovascular death due heart failure than patients with 2MACE score <3 (0.17%/year vs 1.09%/year; p=0.003). 2MACE score had suitable predictive performance for MACE (AUC 0.638 [(0.534–0.742); p=0.010).
Conclusion
In a Real-world AF patients under rivaroxaban therapy from EMIR registry, the 2MACE score is a good predictor of long-term cardiovascular events, MACE and major bleeding. A 2MACE score ≥3 categorize patients at “high-risk” with almost 4-fold risk of MACE in a long-term follow-up.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Bayer Hispania S.L. Table 1. Adverse events according to 2MACE
Collapse
Affiliation(s)
- M Esteve Pastor
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - F Marin
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - M Anguita
- University Hospital Reina Sofia, Cordoba, Spain
| | | | - C Rafols
- Bayer Hispania S.L., Medical Affairs Department, Sant Joan Despí, Spain
| | | | | | - V Barrios
- Hospital Ramon y Cajal, Madrid, Spain
| | - J Cosin Sales
- University Hospital Arnau de Vilanova, Valencia, Spain
| | - R Freixa Pamias
- Hospital Sant Joan Despi Moises Broggi, Sant Joan Despi (Barcelona), Spain
| | - A Perez Cabeza
- University Hospital Virgen de la Victoria, Malaga, Spain
| | | | | | | |
Collapse
|
19
|
Marin F, Rivera-Caravaca J, Anguita Sanchez M, Sanmartin Fernandez M, Rafols C, Roldan V, Recalde E, Freixa Pamias R, Lekuona Goya I, Vazquez Rodriguez J, Perez Cabeza A. Predictors of adverse clinical outcomes in atrial fibrillation patients with concomitant renal impairment under rivaroxaban therapy. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) increases the risk of stroke and mortality, and concomitant renal impairment confers a worse prognosis. However, those factors that may limit the use of direct-acting oral anticoagulants in AF patients with renal impairment have not been further investigated, as they confer a higher risk of adverse events in this patient population.
Purpose
To investigate predictors of adverse clinical outcomes in AF patients with renal impairment who were treated with rivaroxaban.
Methods
The EMIR study is an observational, multicenter study including patients with AF treated with rivaroxaban for at least the previous 6 months. During 2.5 years of follow-up, the occurrence of thromboembolic events (the composite of isquemic stroke, transient ischemic attack, systemic embolism and myocardial infarction [MI]), major bleeding (ISTH definition) and major adverse cardiovascular events (MACE: fatal/non-fatal MI, myocardial revascularization and cardiovascular death) were recorded. For the present analysis, creatinine clearance (CrCl) was estimated by using the Cockroft-Gault equation and renal impairment was defined as a CrCl <60 mL/min.
Results
1433 patients were included (44.5% female; mean age 74.2±9.7 years), of which 498 (35.1%) had CrCl <60 mL/min. The mean CHA2DS2-VASc and HAS-BLED were 3.5±1.5 and 1.6±1.0, respectively. During the follow-up, 7 (1.4%) patients with CrCl <60 mL/min suffered a thromboembolic event, 16 (3.2%) suffered major bleeding, and 19 (3.8%) suffered a MACE. Compared to patients with normal renal function, patients with CrCl <60 mL/min showed a higher annual rate of major bleeding (0.62%/year vs. 1.87%/year; p=0.003) and MACE (0.62%/year vs. 1.97%/year; p=0.002). Multivariate analyses demonstrated that the CHA2DS2-VASc score (OR 1.84; 95% CI 1.11–3.07) was associated with a higher risk of thromboembolic events; whereas the HAS-BLED score (OR 2.25; 95% CI 1.41–3.59) and any dependency level (OR 3.42; 95% CI 1.17–9.98) were associated with a higher risk of major bleeding; and male sex (OR 3.55; 95% CI 1.08–11.63) and heart failure (OR 4.67; 95% CI 1.62–13.51) with a higher risk of MACE. The use of antiplatelet agents was also independently associated with an increased risk of thromboembolic events and MACE (OR 12.28; 95% CI 2.50–60.18; and OR 8.72; 95% CI 2.86–26.59; respectively).
Conclusions
Rivaroxaban showed excellent results in moderate renal impairment. However, the annual rate of major bleeding and MACE was higher in AF patients with impaired renal function. In patients with AF and renal impairment, male sex, the presence of heart failure, dependency, the concomitant use of antiplatelets, and greater comorbidity according to the CHA2DS2-VASc and HAS-BLED, were associated with higher risk of adverse clinical outcomes.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Bayer
Collapse
Affiliation(s)
- F Marin
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - J.M Rivera-Caravaca
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | | | | | - C Rafols
- Bayer Hispania, Barcelona, Spain
| | - V Roldan
- University Hospital Morales Meseguer, University of Murcia, Murcia, Spain
| | - E Recalde
- Centro Médico San Juan de Dios, Barakaldo, Spain
| | | | | | | | - A Perez Cabeza
- University Hospital Virgen de la Victoria, Malaga, Spain
| |
Collapse
|
20
|
Ding W, Proietti M, Boriani G, Marin F, Blomstrom-Lundqvist C, Fauchier L, Potpara T, Lip G. Digoxin vs. beta-blocker therapy in atrial fibrillation: analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
There is a long-standing and unresolved controversy over the effects of digoxin on mortality. Furthermore, there is scarce evidence comparing the use of digoxin to beta-blocker in the general population with atrial fibrillation (AF). In this study, we aimed to evaluate the effects of digoxin over beta-blocker therapy among patients with AF.
Methods
Patients from the EORP-AF General Long-Term Registry with AF who were treated with either digoxin or beta-blocker were included. All patients were over 18 years old and had documented evidence of AF within 12 months prior to enrolment. The outcomes of interest were all-cause mortality, cardiovascular (CV) mortality, non-CV mortality and number of patients with unplanned hospitalisation (total and AF-related). These were recorded until the last known follow-up available.
Results
Of 6377 patients, 549 (8.6%) and 5828 (91.4%) were treated with digoxin and beta-blockers, respectively. Patients in the digoxin group were older (73 vs. 71 years, p<0.001) with reduced renal function (eGFR 65.4 vs. 68.7 mL/min/1.73m2, p=0.002), and had (in general) greater burden of comorbidities in terms of chronic kidney disease, chronic obstructive pulmonary disease, heart failure, hypertension and peripheral artery disease. Nonetheless, the use of anticoagulation therapy was comparable between both groups (p=0.112).
Over 24 months follow-up, there were 550 (8.6%) all-cause mortality and 1304 (23.6%) patients with unplanned emergency hospitalisation. Digoxin use was associated with increased all-cause mortality (hazard ratio [HR] 1.90 [95% CI, 1.48–2.44]), both from CV and non-CV causes (CV: HR 2.21 [95% CI, 1.49–3.26]); non-CV: HR 1.70 [95% CI, 1.04–2.79]). There was no statistical difference in terms of unplanned emergency hospitalisation (HR 0.99 [95% CI, 0.80–1.21]) and AF-related hospitalisation (HR 0.78 [95% CI, 0.58–1.06]) between both groups.
Using multivariable cox regression analysis, digoxin compared to beta-blocker therapy was independently linked to increased all-cause mortality (HR 1.52 [95% CI, 1.11–2.09]) and CV mortality (HR 1.82 [95% CI, 1.11–2.97]), but was not related to non-CV mortality (HR 1.31 [95% CI, 0.71–2.41]), emergency hospitalisation (HR 0.91 [95% CI, 0.71–1.16]) or AF-related hospitalisation (HR 0.88 [95% CI, 0.62–1.24]), after adjustment for known risk factors.
Conclusion
We demonstrated that the use of digoxin was independently associated with excess all-cause mortality, driven by CV death, but was non-inferior to beta-blocker in terms of preventing unplanned emergency or AF-related hospitalisation, after accounting for important risk factors.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- W.Y Ding
- University of Liverpool, Liverpool, United Kingdom
| | | | - G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | - F Marin
- University of Murcia, Murcia, Spain
| | | | - L Fauchier
- University Hospital of Tours, Tours, France
| | | | - G.Y.H Lip
- University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
21
|
Malavasi VL, Vitolo M, Proietti M, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Lane DA, Lip GYH, Boriani G. Impact of malignancy on outcomes in European patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation General Long-Term Registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Management of patients with atrial fibrillation (AF) and malignancy is a clinical challenge given the paucity of evidence supporting the appropriate clinical management.
Purpose
To evaluate the outcomes of patients with active or prior malignancy in a large contemporary cohort of European AF patients.
Methods
We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. We stratified the population into three categories (i) No Malignancy (NoM) (ii) Prior Malignancy (PriorM) and (iii) Active Malignancy (ActM). The primary outcome for this analysis was all-cause death among the three groups. The association between anticoagulant treatment, all-cause death and haemorrhagic events was also evaluated.
Results
Among the original 11 096 AF patients enrolled, 10 383 were included in this analysis (median age 71 years (interquartile range [IQR] 63–77, males 59.7%). Of these, 9 597 (92.4%) were NoM patients, 577 (5.6%) PriorM and 209 (2%) ActM. Patients with malignancy (prior or active) had a higher median age, median CHA2DS2-VASc and HAS-BLED scores, compared to patients without malignancy (p<0.001). Lack of anticoagulation (AC) prescription occurred more commonly in ActM (21.5%) as compared with the other groups (PriorM 10.1% vs NoM 12.8%, p<0.001). In case of AC treatment, patients with ActM were treated more frequently with heparins (ActM 8.1% vs PriorM 2.4% vs NoM 2%, p<0.001).
After a median follow-up of 730 days [IQR 692–749], 982 (9.5%) patients died. Among all deaths, the proportion of cardiovascular death was different according to the three groups (40.0% in NoM, 26.0% in PrioM and 22.2% in ActM, p=0.002). For all cause-death, Kaplan-Meier analysis showed a progressively higher cumulative risk in the PriorM and ActM groups compared to NoM patients (Figure 1).
On multivariable Cox regression analysis, adjusted for CHA2DS2-VASc score, use of AC, type of AF and chronic kidney disease, ActM group was independently associated with a higher risk for all cause death (hazard ratio [HR] 2.90, 95% confidence interval [CI] 2.23–3.76) while PriorM group was not.
Among PriorM and NoM patients, multivariable adjusted Cox regression analysis found that the use of any AC was independently associated with a lower risk for all-cause death (HR 0.36, 95% CI 0.19–0.66; HR 0.66, 95% CI 0.54–0.81). No significant association between AC and all-cause death was found for ActM patients.
Conclusions
In a large contemporary cohort of European AF patients, active malignancy was found to be independently associated with all-cause death. Use of any AC was associated with a lower risk for all-cause death in patients with no malignancies and with prior malignancies, but with no significant association amongst patients with active malignancies.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022). Figure 1. Kaplan-Meier for all-cause death
Collapse
Affiliation(s)
- V L Malavasi
- University of Modena & Reggio Emilia, Modena, Italy
| | - M Vitolo
- University of Modena & Reggio Emilia, Modena, Italy
| | - M Proietti
- University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy
| | - L Fauchier
- University Hospital of Tours, Tours, France
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - M Nabauer
- Ludwig Maximilians University Hospital, Munich, Germany
| | - T S Potpara
- University Belgrade Medical School, Belgrade, Serbia
| | - G A Dan
- Colentina University Hospital, Bucharest, Romania
| | - Z Kalarus
- Silesian Center for Heart Diseases (SCHD), Zabrze, Poland
| | - D A Lane
- University of Liverpool, Liverpool, United Kingdom
| | - G Y H Lip
- University of Liverpool, Liverpool, United Kingdom
| | - G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | | |
Collapse
|
22
|
Esteve Pastor M, Marin F, Anguita M, Sanmartin M, Rafols C, Roldan V, Perez C, Barrios V, Lekuona Goya I, Perez Cabeza A, Cosin Sales J. Oral anticoagulation therapy with rivaroxaban in elderly patients with atrial fibrillation. Results from EMIR study. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) in elderly patients increases both bleeding and thromboembolic risks. Elderly patients benefit as much from anticoagulation therapy with positive net clinical benefit. However, there have been few studies that focused on the efficacy and safety of direct oral anticoagulants in elderly patients.
The aim of this subanalysis from EMIR study was to assess the effectiveness of rivaroxaban in patients older than 75 years old.
Methods
EMIR Study (acronym from 'Estudio observacional para la identificaciόn de los factores de riesgo asociados a eventos cardiovasculares Mayores en pacientes con fIbrilaciόn auricular no valvular tratados con un anticoagulante oral directo (Rivaroxaban)') was an observational, multicenter, post-authorization and prospective study that involved AF patients under oral anticoagulation with rivaroxaban at least 6 months before enrolment. We analyzed baseline clinical characteristics and adverse events after 2.5 years of follow up.
Results
We analyzed 1,433 patients with median age of 74.7 (67.7–81.6). Of them 691 (48.2%) were ≥75 years. Elderly patients had higher prevalence of cardiovascular risk factors such previous stroke (16.8% vs 8.5%; p<0.001), heart failure (25.0% vs 20.6%; p<0.001), higher CHA2DS2-VASc (4.4±1.3 vs 2.7±1.2; p<0.001) and HAS-BLED (1.9±1.0 vs 1.2±1.0; p<0.001) scores. After 2.5 (2.2–2.6) years of follow-up, we observed low rate of adverse events in patients under rivaroxaban therapy. We observed higher rate of adverse events in elderly population for thromboembolic events (1.13%/year vs 0.36%/year; p=0.017) and major bleeding events (1.80%/year vs 0.36%/year; p<0.001) but those adverse rates were lower than expected according to previous studies (i.e. ROCKET-AF trial, rivaroxaban group had 4.86%/year of major bleeding or in XANTUS study was 3.2%/year of major bleeding in patients >75 years). We did not observe differences between groups from MACE (1.13%/year vs 1.01%/year; p=0.875) or cardiovascular death (0.86%/year vs 0.42%/year; p=0.170).
Conclusion
In real-world elderly population, rivaroxaban showed higher rates of thromboembolic and major bleeding events in elderly patients but with annual rates lower than expected according to previous studies like ROCKET-AF or XANTUS. Similar annual rates in elderly were observed for MACE and cardiovascular mortality than in younger patients, being rivaroxaban a good therapeutic alternative even for the elderly.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Bayer Hispania S.L.
Collapse
Affiliation(s)
- M Esteve Pastor
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - F Marin
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - M Anguita
- University Hospital Reina Sofia, Cordoba, Spain
| | | | - C Rafols
- Bayer Hispania S.L., Medical Affairs Department, Sant Joan Despí, Spain
| | - V Roldan
- University Hospital Morales Meseguer, Murcia, Spain
| | - C Perez
- General Hospital of Jerez, Cadiz, Spain
| | - V Barrios
- Hospital Ramon y Cajal, Madrid, Spain
| | | | - A Perez Cabeza
- University Hospital Virgen de la Victoria, Malaga, Spain
| | | | | |
Collapse
|
23
|
Ding W, Proietti M, Boriani G, Marin F, Blomstrom-Lundqvist C, Fauchier L, Potpara T, Lip G. Clinical application of the novel 4S-AF scheme for the characterisation of patients with atrial fibrillation: a report from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Current classification systems recommended by major international guidelines are based on a single domain of atrial fibrillation (AF): temporal pattern, symptom severity or underlying comorbidity. Lack of integration between these various elements limits our approach to patients with AF and acts as a barrier against the delivery of better holistic care. The 4S-AF classification scheme was recently introduced as a means for the characterisation of patients with AF. It comprises of 4 domains: stroke risk (St), symptoms (Sy), severity of AF burden (Sb) and substrate (Su). We sought to examine the implementation of the 4S-AF scheme in the EORP-AF General Long-Term Registry and effects of individual domains on outcomes in AF.
Methods
Patients with AF from 250 centres across 27 participating European countries were included. All patients were over 18 years old and had electrocardiographic confirmation of AF within 12 months prior to enrolment. Data on demographics and comorbidities were collected at baseline. Individual domains of the 4S-AF scheme were assessed using the CHA2DS2-VASc score (St), European Heart Rhythm Association classification (Sy), temporal classification of AF (Sb), and cardiovascular risk factors and the degree of left atrial enlargement (Su). Each of these domains were used during multivariable cox regression analysis.
Results
A total of 6321 patients were included in the present analysis, corresponding to 57.0% of the original cohort of 11096 patients. The median age of patients was 70 (interquartile range [IQR] 62–77) years with 2615 (41.4%) females. Among these patients, 528 (8.4%) had low stroke risk (St=0), 3002 (47.5%) no or mild symptoms (Sy=0), 2558 (40.5%) newly diagnosed or paroxysmal AF (Sb=0), and 322 (5.1%) no cardiovascular risk factors or left atrial enlargement (Su=0).
Median follow-up was 24 months. Using multivariable cox regression analysis, independent predictors of all-cause mortality were (St) (adjusted hazard ratio [aHR] 8.21 [95% CI, 2.60–25.9]), (Sb) (aHR 1.21 [95% CI, 1.08–1.35]) and (Su) (aHR 1.27 [95% CI, 1.14–1.41]). For cardiovascular mortality and any thromboembolic event, only (Su) (aHR 1.73 [95% CI, 1.45–2.06]) and (Sy) (aHR 1.29 [95% CI, 1.00–1.66]) were statistically important, respectively. None of the domains were independently linked to ischaemic stroke or major bleeding.
Conclusion
Overall, we demonstrated that the 4S-AF scheme may be used to provide clinical characterisation of patients with AF using routinely collected data, and each of the domains within the 4S-AF scheme were independently associated with adverse long-term outcomes of all-cause mortality, cardiovascular mortality and/or any thromboembolic event.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- W.Y Ding
- University of Liverpool, Liverpool, United Kingdom
| | | | - G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | - F Marin
- University of Murcia, Murcia, Spain
| | | | - L Fauchier
- University Hospital of Tours, Tours, France
| | | | - G.Y.H Lip
- University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
24
|
Ding W, Rivera-Caravaca J, Marin F, Roldan V, Lip G. Stroke risk based on classification of atrial fibrillation: real-world vs clinical trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The most widely accepted clinical classification of atrial fibrillation (AF) is according to temporal rhythm-based patterns, reflecting the notion that most patients initially suffer from transient episodes that prolong over time due to atrial substrate remodelling as the disease progresses. Therefore, it may be speculated that patients with extended episodes of “continuous” AF (persistent, long-standing persistent and permanent AF) may be at higher risk of stroke complications compared to paroxysmal AF (pAF). However, the risk of stroke according to clinical classification of AF remains poorly defined. In this study, we assessed the impact of AF type on stroke risk in patients with AF from “real-world” and “clinical trial” cohorts.
Methods
Post-hoc analysis of patient-level data from the Murcia AF Project and AMADEUS trial. All patients were anticoagulated. Patients were grouped into those with pAF and non-pAF. pAF was defined as AF that terminates spontaneously or with intervention within seven days of onset. Non-pAF was defined as AF that lasted longer than seven days, including persistent, long-standing persistent and permanent AF subtypes. Study endpoint was the incidence rate of ischaemic stroke. A modified CHA2DS2-VAS“c” score that applied one additional point for a “c” criterion of continuous AF (i.e. non-pAF) was calculated.
Results
5,917 patients were included; 1,361 (23.0%) real-world and 4,556 (77.0%) clinical trial. Real-world patients had a median age of 76 (interquartile range [IQR] 71–81) years with 51.3% females compared to a median age of 71 (IQR 64–77) years with 33.5% females among clinical trial participants. Baseline demographics were comparable in both groups in the real-world cohort but clinical trial participants with non-pAF were older, predominantly male and had more comorbidities compared to those with pAF.
Crude stroke rates were comparable between the groups in real-world patients (incidence rate ratio [IRR] 0.72 [95% CI, 0.37–1.28], p=0.259) though clinical trial participants with non-pAF (vs. pAF) had a significantly higher crude rate of stroke events (IRR 4.66 [95% CI, 2.41–9.48], p<0.001). Using multivariable cox regression analysis, AF type was not independently associated with stroke risk in the real-world (adjusted hazard ratio [HR] 1.41 [95% CI, 0.80–2.50], p=0.239) and clinical trial (adjusted HR 1.17 [95% CI, 0.62–2.20], p=0.621) cohorts, after accounting for known risk factors using the CHA2DS2-VASc score. Using receiver operating characteristic curves analysis, we found no significant improvement in the CHA2DS2-VAS“c” compared to CHA2DS2-VASc score in either cohort (p>0.05).
Conclusion
Overall, there was no association between the temporal rhythm-based patterns of AF and stroke risk among anticoagulated patients, suggesting that this should not be a consideration when assessing the need for anticoagulation in AF.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- W.Y Ding
- University of Liverpool, Liverpool, United Kingdom
| | | | - F Marin
- University of Murcia, Murcia, Spain
| | - V Roldan
- University of Murcia, Murcia, Spain
| | - G.Y.H Lip
- University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
25
|
Anguita Sanchez M, Ruiz Ortiz M, Marin F, Sanmartin M, Rafols C, Masjuan J, Urena I, Baron Esquivias G, Lekuona I, Perez Cabeza A, Vazquez Rodriguez J. Incidence of cardiovascular events in patients with atrial fibrillation anticoagulated with rivaroxaban after 2.5 years of follow-up: not all is stroke or bleeding. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Atrial fibrillation (AF) is not a benign arrhythmia, but is associated with an increase in mortality, above all related to the risk of suffering thromboembolic events, mainly stroke. The use of oral anticoagulants (OAC) reduces this risk, but increases the risk of serious bleeding. The DOACs have been shown to be superior to the classic vitamin K antagonists (VKAs). It is not as well known whether AF is associated with an increase in other serious cardiac events.
Purpose
The objective of this analysis was to assess the incidence of stroke, major bleeding, total mortality and major adverse cardiac events [MACE, defined as cardiac mortality (including death for coronary events, progressive heart failure death and sudden cardiac death), coronary revascularization, myocardial infarction] in a contemporary series of patients with AF anticoagulated with rivaroxaban.
Methods
To do this, we have analyzed a series of 1,433 patients with AF, anticoagulated with rivaroxaban for at least the previous 6 months, consecutively included in the first half of year 2017 in 79 Spanish centers (EMIR study), and followed for 2.5 years.
Results
Mean age was 74.2±9.7 years, 44.5% being women. Prevalence of diabetes was 27.1%, chronic renal failure 16.1%, coronary heart disease 16.4% and heart failure 22.7%. 2MACE score was 1.8±1.4, CHA2DS2-VASc was 3.5±1.5 and HAS-BLED 1.6±1.0. 77.1% of patients received 20 mg/ day of rivaroxaban and 22.9% 15 mg/day. After a follow-up of 2.5 years, the annual rate (events/100 patients/year) of myocardial infarction was 0.16 (all non-STEMI), coronary revascularization 0.28, cardiac death 0.63 (sudden 0.16, heart failure 0.41, other 0.06), overall MACE 1.07 and overall mortality 2.73, while the incidence of stroke was 0.57 / 100 patients / year (ischemic 0.35, haemorrhagic 0.22) and major bleeding 1.04 (gastrointestinal 0.63, intracranial 0.28).
Conclusion
In a current series of patients with AF anticoagulated with rivaroxaban, the incidence of embolic and hemorrhagic complications and mortality are low, while the incidence of serious cardiac events is significant, being overall similar to that of stroke and major bleeding. Attention must be paid to the prevention and diagnosis of these problems.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Bayer Hispania
Collapse
Affiliation(s)
| | - M Ruiz Ortiz
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| | - F Marin
- University Hospital Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - M Sanmartin
- University Hospital Ramon y Cajal, Cardiology, Madrid, Spain
| | - C Rafols
- Bayer Hispania, Medical Department, Barcelona, Spain
| | - J Masjuan
- University Hospital Ramon y Cajal, Neurology, Madrid, Spain
| | - I Urena
- Hospital Morales Meseguer, Cardiology, Murcia, Spain
| | | | - I Lekuona
- University Hospital Galdacano, Cardiology, Bilbao, Spain
| | - A Perez Cabeza
- University Hospital Virgen de la Victoria, Cardiology, Malaga, Spain
| | | | | |
Collapse
|
26
|
Proietti M, Vitolo M, Harrison S, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH. Impact on outcomes in Europe: a cluster analysis from the ESC-EHRA EORP AF general long-term registry. Europace 2021. [DOI: 10.1093/europace/euab116.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
OnBehalf
ESC-EHRA EORP AF General Long-Term Registry Investigators
Introduction
Data derived from recent observational studies in atrial fibrillation (AF) show how the complexity of the clinical phenotype, beyond baseline thromboembolic risk, can increase risk of major adverse outcomes. Importantly, risk factors tend to occur in clusters, rather than occur individually in isolation.
Aims
To describe AF patients’ clinical phenotypes among a large contemporary European AF cohort and to analyse the differential impact of these clinical phenotypes on the occurrence of major adverse outcomes.
Methods
We performed a hierarchical cluster analysis based on Ward’s Method and using Squared Euclidean Distance using 22 clinical covariates. All variables were considered as binary. Examining the distances between cluster coefficients and by visual inspection of the dendrogram produced we identified the optimal number of clusters. Patients with data available for all 22 variables were included. We considered occurrence of cardiovascular events and all-cause death.
Results
Among the original 11096 patients included, 9363 (84.4%) were available for this analysis. The cluster analysis identified three clusters: Cluster 1 (n = 3634; 38.8%) characterized by older patients with prevalent noncardiac comorbidities; Cluster 2 (n = 2774; 29.6%) characterized by younger patients mainly admitted for first detected and paroxysmal AF with low prevalence of concomitant conditions; Cluster 3 (n = 2955; 31.6%) included patients with high prevalence of permanent AF, cardiac risk factors and comorbidities. Thromboembolic and bleeding risks were higher in Cluster 3 and progressively lower in Cluster 1 and Cluster 2 (both p < 0.001). Use of oral anticoagulant was significantly lower for Cluster 2 (83.2% vs. 86.5% and 86.7% in Cluster 1 and Cluster 3, respectively; p < 0.001). Over a mean follow-up of 22.5 (SD5.5) months, Cluster 3 had the highest rate of both cardiovascular events (10.0%) and all-cause death (13.2%), compared with Cluster 1 (6.6% and 9.4%, respectively) and Cluster 2 (3.7% and 3.8%, respectively) (both p < 0.001). Kaplan-Meier curves (Figure) show that Cluster 2 (green line) had the lowest cumulative risk of outcomes; risk was progressively higher in Cluster 1 (orange line) and Cluster 3 (yellow line). A Cox multivariable regression analysis, adjusted for type of AF, symptomatic status, CHA2DS2-VASc score and use of oral anticoagulants, showed that both Cluster 3 and Cluster 1 were associated with a significantly increased risk of cardiovascular events (HR: 1.80, 95%CI: 1.39-2.33 and HR: 1.40, 95%CI: 1.09-1.80, respectively) and all-cause death (HR: 1.80, 95%CI: 1.40-2.30 and HR: 1.66, 95%CI: 1.30-2.11) compared to Cluster 2.
Conclusions
In European AF patients, three main clinical clusters were identified, those with non-cardiac comorbidities, low risk and cardiac comorbidities. Both non-cardiac and cardiac comorbidities clusters were found to be associated with an increased risk of cardiovascular events and all-cause death. Abstract Figure. Kaplan-Meier Curves for Outcomes
Collapse
Affiliation(s)
| | - M Vitolo
- University of Modena & Reggio Emilia, Modena, Italy
| | - S Harrison
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - DA Lane
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - L Fauchier
- University Hospital of Tours, Tours, France
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - M Nabauer
- Ludwig Maximilians University Hospital, Munich, Germany
| | - TS Potpara
- University of Belgrade, Belgrade, Serbia
| | - GA Dan
- Colentina University Hospital, Bucharest, Romania
| | - G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | - GYH Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
27
|
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lip GYH. Association between thromboembolic and bleeding risk with adverse outcomes in contemporary European atrial fibrillation patients: final analysis from the ESC-EHRA EORP AF general long-term registry. Europace 2021. [DOI: 10.1093/europace/euab116.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
The ESC-EHRA EORP AF General Long-Term Registry provides a contemporary snapshot of European atrial fibrillation (AF) patients’ characteristics and management. Aims: We present data about the final 2-years follow-up observation of AF patients enrolled in the ESC-EHRA EORP AF General Long-Term Registry.
Methods
A contemporary evaluation of residual risk of adverse outcomes in a cohort of largely anticoagulated AF patients according to the baseline thromboembolic and bleeding risk, defined according to CHA2DS2-VASc and HAS-BLED scores. We determined cardiovascular (CV) events, CV death and all-cause death as outcomes.
Results
Among the original 11069 patients enrolled, 8409 (76.0%) patients had available follow-up status at the end of the 2-years follow-up. Patients age, female sex and most comorbidities were progressively more prevalent across the spectrum of thromboembolic and bleeding risk. Data on adverse outcomes were available for 10087 (91.1%), over the 2-year observation period. Outcome rates were progressively higher across CHA2DS2-VASc and HAS-BLED scores (all p < 0.0001). A fully adjusted Cox multivariable regression analysis, adjusted for clinical covariates selected by a univariate procedure and not included in the scores, showed that increasing baseline CHA2DS2-VASc score was associated with an higher risk for CV events (hazard ratio [HR]: 1.25, 95% confidence interval [CI]: 1.21-1.30), CV death (HR: 1.31, 95%CI: 1.25-1.38) and all-cause death (HR: 1.30, 95%CI: 1.25-1.36). Similarly, increasing baseline HAS-BLED score was associated with an increased risk for all 3 outcomes (HR: 1.21, 95%CI: 1.13-1.28; HR: 1.24, 95%CI: 1.14-1.34; HR: 1.22, 95%CI: 1.14-1.31, respectively). An association with a progressively higher risk was found for all outcomes across the spectrum of thromboembolic and bleeding risk [Figure]. Both CHA2DS2-VASc and HAS-BLED scores showed a modest to good predictive ability for cardiovascular (CV) events, CV death and all-cause death, in terms of c-index and 95% CI[0.66 (0.64-0.68) and 0.62 (0.61-0.64), 0.70 (0.68-0.72) and 0.65 (0.63-0.67), 0.69 (0.68-0.71) and 0.64 (0.63-0.66) for CHA2DS2-VASc and HAS-BLED for each outcome respectively.
Conclusions
In this large contemporary European-wide cohort of AF patients, both baseline thromboembolic and bleeding risks were associated to an increased risk of major clinical outcomes. Both scores are reflective of high risk clinical states, and are predictive of major adverse outcomes even in a large cohort of largely anticoagulated patients with a lower residual risk of adverse outcomes. Abstract Figure.
Collapse
Affiliation(s)
- G Boriani
- University of Modena & Reggio Emilia, Modena, Italy
| | | | - C Laroche
- European Society of Cardiology, Sophia-Antipolis, France
| | - L Fauchier
- University Hospital of Tours, Tours, France
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - M Nabauer
- University Hospital of Munich, Munich, Germany
| | - T Potpara
- Clinical center of Serbia, Belgrade, Serbia
| | - GA Dan
- Carol Davila Emergency Clinical Military Hospital, Bucharest, Romania
| | - Z Kalarus
- Silesian Center for Heart Diseases (SCHD), Zabrze, Poland
| | - L Tavazzi
- Maria Cecilia Hospital, Cotignola, Italy
| | - AP Maggioni
- European Society of Cardiology, Sophia-Antipolis, France
| | - GYH Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
28
|
Ding WY, Rivera-Caravaca JM, Marin F, Torp-Pedersen C, Roldan V, Lip GYH. Novel tool for predicting residual stroke risk in atrial fibrillation: mCARS. Europace 2021. [DOI: 10.1093/europace/euab116.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Recently, CARS was proposed to predict 1-year absolute stroke risk in non-anticoagulated patients with atrial fibrillation (AF). We aimed to determine whether a modified CARS (mCARS) may be used to assess the residual stroke risk in anticoagulated AF patients.
Methods
We studied patient-level data of anticoagulated AF patients from the real-world Murcia AF Project and AMADEUS clinical trial. Individual mCARS was estimated for each patient using an estimated 64% risk reduction with anticoagulation.
Results
3,503 patients were included (2,205 [62.9%] clinical trial and 1,298 [37.1%] real-world). In the clinical trial cohort, the median age was 71 (IQR 65-77) and CHA2DS2-VASc score 3 (IQR 2-4). In the real-world cohort, the median age was 76 (IQR 70-81) and CHA2DS2-VASc score 4 (IQR 3-5).
At 1-year, there were 40 and 31 stroke events in the clinical trial and real-world cohorts, respectively. Average predicted residual stroke risk by mCARS was identical to actual stroke risk (1.8 [±1.8%] vs. 1.8% [95% CI, 1.3-2.4]) in the clinical trial, and broadly similar in the real-world (2.1 [±1.9%] vs. 2.4% [95% CI, 1.6-3.4]). Additionally, these values were comparable across the subgroups stratified by CHA2DS2-VASc score in both cohorts.
AUCs of mCARS for prediction of stroke events in the clinical trial and real-world were 0.678 (95% CI, 0.598-0.758) and 0.712 (95% CI, 0.618-0.805), respectively. In an exploratory analysis, we found that mCARS was able to refine stroke risk estimation for each point of the CHA2DS2-VASc score in both cohorts.
Conclusion
Personalised residual 1-year absolute stroke risk in anticoagulated AF patients may be estimated using mCARS. Such patients with high residual stroke risk may benefit from more aggressive interventions and follow-up. Absolute 1-year stroke risk Clinical Trial Real-World Median (IQR) Range Median (IQR) Range CHA2DS2-VASc score 0 NA 0.9 (0.6 - 1.3) 0.2 - 1.4 CHA2DS2-VASc score 1 1.1 (0.7 - 1.4) 0.2 - 2.0 1.4 (0.9 - 1.7) 0.2 - 13.0 CHA2DS2-VASc score 2 2.0 (1.5 - 2.4) 0.3 - 10.8 2.1 (1.5 - 2.6) 0.3 - 10.8 CHA2DS2-VASc score 3 2.6 (2.1 - 3.4) 0.4 - 13.3 2.8 (2.5 - 3.4) 0.9 - 13.3 CHA2DS2-VASc score 4 3.6 (2.8 - 5.6) 0.3 - 18.1 3.9 (3.3 - 5.0) 1.1 - 21.0 CHA2DS2-VASc score 5 6.7 (3.6 - 14.0) 1.9 - 20.9 4.8 (3.9 - 12.2) 1.2 - 21.0 CHA2DS2-VASc score 6 13.6 (5.5 - 15.8) 2.4 - 21.8 12.8 (4.8 - 16.7) 2.2 - 21.8 CHA2DS2-VASc score 7 15.7 (14.5 - 17.4) 4.5 - 21.9 15.6 (5.9 - 17.5) 4.1 - 23.5 CHA2DS2-VASc score 8 16.5 (14.0 - 18.5) 13.1 - 20.3 16.9 (15.7 - 19.5) 13.6 - 21.0 IQR, interquartile range; NA, not applicable.
Collapse
Affiliation(s)
- WY Ding
- University of Liverpool, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - JM Rivera-Caravaca
- University of Liverpool, Liverpool, United Kingdom of Great Britain & Northern Ireland
| | - F Marin
- University of Murcia, Murcia, Spain
| | | | - V Roldan
- University of Murcia, Murcia, Spain
| | - GYH Lip
- University of Liverpool, Liverpool, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
29
|
Cheli A, Mancuso A, Azzarone M, Fermani S, Kaandorp J, Marin F, Montroni D, Polishchuk I, Prada F, Stagioni M, Valdré G, Pokroy B, Falini G, Goffredo S, Scarponi D. Climate variation during the Holocene influenced the skeletal properties of Chamelea gallina shells in the North Adriatic Sea (Italy). PLoS One 2021; 16:e0247590. [PMID: 33661962 PMCID: PMC7932108 DOI: 10.1371/journal.pone.0247590] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 02/09/2021] [Indexed: 12/01/2022] Open
Abstract
Understanding how marine taxa will respond to near-future climate changes is one of the main challenges for management of coastal ecosystem services. Ecological studies that investigate relationships between the environment and shell properties of commercially important marine species are commonly restricted to latitudinal gradients or small-scale laboratory experiments. This paper aimed to explore the variations in shell features and growth of the edible bivalve Chamelea gallina from the Holocene sedimentary succession to present-day thanatocoenosis of the Po Plain-Adriatic Sea system (Italy). Comparing the Holocene sub-fossil record to modern thanatocoenoses allowed obtaining an insight of shell variations dynamics on a millennial temporal scale. Five shoreface-related assemblages rich in C. gallina were considered: two from the Middle Holocene, when regional sea surface temperatures were higher than today, representing a possible analogue for the near-future global warming, one from the Late Holocene and two from the present-day. We investigated shell biometry and skeletal properties in relation to the valve length of C. gallina. Juveniles were found to be more porous than adults in all horizons. This suggested that C. gallina promoted an accelerated shell accretion with a higher porosity and lower density at the expense of mechanically fragile shells. A positive correlation between sea surface temperature and both micro-density and bulk density were found, with modern specimens being less dense, likely due to lower aragonite saturation state at lower temperature, which could ultimately increase the energetic costs of shell formation. Since no variation was observed in shell CaCO3 polymorphism (100% aragonite) or in compositional parameters among the analyzed horizons, the observed dynamics in skeletal parameters are likely not driven by a diagenetic recrystallization of the shell mineral phase. This study contributes to understand the response of C. gallina to climate-driven environmental shifts and offers insights for assessing anthropogenic impacts on this economic relevant species.
Collapse
Affiliation(s)
- Alessandro Cheli
- Marine Science Group, Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
| | - Arianna Mancuso
- Marine Science Group, Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
| | - Michele Azzarone
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Simona Fermani
- Department of Chemistry ‘Giacomo Ciamician’, University of Bologna, Bologna, Italy
| | - Jaap Kaandorp
- Computational Science Laboratory, Faculty of Science, University of Amsterdam, Amsterdam, The Netherlands
| | - Frederic Marin
- UMR CNRS 6282 Biogéosciences, Université de Bourgogne—Franche-Comté, Dijon, France
| | - Devis Montroni
- Department of Chemistry ‘Giacomo Ciamician’, University of Bologna, Bologna, Italy
| | - Iryna Polishchuk
- Department of Materials Sciences and Engineering and the Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Technion City, Haifa, Israel
| | - Fiorella Prada
- Marine Science Group, Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
| | - Marco Stagioni
- Marine Biology and Fisheries Laboratory of Fano, Department of Biological, Geological and Environmental Sciences, University of Bologna, Italy
| | - Giovanni Valdré
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Boaz Pokroy
- Department of Materials Sciences and Engineering and the Russell Berrie Nanotechnology Institute, Technion–Israel Institute of Technology, Technion City, Haifa, Israel
| | - Giuseppe Falini
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
- Department of Chemistry ‘Giacomo Ciamician’, University of Bologna, Bologna, Italy
- * E-mail: (GF); (SG); (DS)
| | - Stefano Goffredo
- Marine Science Group, Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
- * E-mail: (GF); (SG); (DS)
| | - Daniele Scarponi
- Fano Marine Center, The Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnologies, Fano, Italy
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
- * E-mail: (GF); (SG); (DS)
| |
Collapse
|
30
|
Minderhoud SCS, Hirsch A, Marin F, Kardys I, Roos-Hesselink JW, Wentzel JJ, Helbing WA, Akyildiz AC. Serial MRI-based right ventricular mechanical wall stress measurements and their association with right ventricle function in patients with repaired Tetralogy of Fallot. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): Stichting Hartekind en Thorax Foundation
Background
Optimal timing of pulmonary valve replacement (PVR) in Tetralogy of Fallot (TOF) patients remains challenging. Wall stress is considered to be a possible early marker of right ventricular (RV) dysfunction. With patient-specific computational models, wall stress can be determined regionally and with high accuracy, especially in complex shaped ventricles such as in TOF patients. We aimed to 1) develop patient-specific computational models to assess RV diastolic wall stresses and 2) investigate the association of wall stresses and their change over time with functional parameters in TOF patients.
Methods
Repaired TOF patients with at least moderate pulmonary regurgitation (PR) and prior to PVR were included. MRI-based patient-specific computational ventricular models were created (figure). The ventricular geometry was created by stacking endo- and epicardial contours traced on short axis SSFP cine images. Pressure in the right ventricle was estimated from echocardiography. Mid-diastolic wall stress in the RV free wall was analysed globally and regionally (basal, mid, apical, anterior, lateral and posterior) at two time points. RV ejection fraction (RVEF), NT-proBNP and exercise tests (% maximum predicted workload) were used as outcomes for RV function. Associations between wall stresses and outcomes were investigated using linear mixed models adjusted for follow-up duration.
Results
Five males and five females were included with an age at baseline of 24 (IQR 16-28) years and RV end-diastolic volume of 140 (IQR 127-144) ml/m2. The period between the two time points was 7.0 (IQR 5.8-7.3) years. Global wall stress of the RV free wall combining both time points was 5.8 kPa (IQR 5.2-7.2). There was no statistical difference between baseline and follow-up global wall stress. The mean wall stresses in the mid region was 1.69 kPa (p < 0.01) higher than in the basal region and was 1.05 kPa (p = 0.03) higher than in the apical region cross-sectionally. The wall stress also increased more in the mid region compared to basal and apical region, corrected for duration of follow-up. Patients with more severe PR at baseline demonstrated a higher increase of global wall stress over time (p = 0.02), especially in lateral free wall. Higher global free wall stresses were cross-sectionally independently associated with lower RVEF, adjusted for LVEF and RVEDV (β=-1.29 % RVEF per kPa increase in wall stress, p = 0.01). This association was most prominent in the anterior, basal and mid part. No statistically significant association was found between wall stress, NT-proBNP, and exercise capacity.
Conclusions
This study generated a novel MRI-based method to calculate wall stress in geometrically complex ventricles. Wall stress associated negatively with RVEF in patients with TOF and PR. This promising tool for RV wall stress analysis can be used in future larger studies to validate these preliminary findings and to assess the predictive value of wall stress in TOF.
Abstract Figure.
Collapse
Affiliation(s)
- SCS Minderhoud
- Erasmus University Medical Centre, Cardiology and Radiology and Nuclear Medicine, Rotterdam, Netherlands (The)
| | - A Hirsch
- Erasmus University Medical Centre, Cardiology and Radiology and Nuclear Medicine, Rotterdam, Netherlands (The)
| | - F Marin
- Politecnico di Milano, Chemistry, Materials and Chemical Engineering “Giulio Natta”, Milan, Italy
| | - I Kardys
- Erasmus University Medical Centre, Cardiology, Rotterdam, Netherlands (The)
| | - JW Roos-Hesselink
- Erasmus University Medical Centre, Cardiology, Rotterdam, Netherlands (The)
| | - JJ Wentzel
- Erasmus University Medical Centre, Cardiology, Rotterdam, Netherlands (The)
| | - WA Helbing
- Erasmus University Medical Centre, Paediatrics and Radiology and Nuclear Medicine, Rotterdam, Netherlands (The)
| | - AC Akyildiz
- Erasmus University Medical Centre, Cardiology, Rotterdam, Netherlands (The)
| |
Collapse
|
31
|
Gomez Polo J, Vivas Balcones D, Marcano Fernandez A, Playan Escribano J, Lugo Gavidia L, Bernardo E, Ortega Pozzi M, De La Hera Galarza J, Tello Montoliu A, Besteiro Vazquez A, Silva I, Marin F, Roldan Rabadan I, Gomez Hospital J, Ferreiro J. Impact of smoking habit on platelet reactivity in a cohort of patients admitted due to an acute coronary syndrome. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Several pharmacodynamic studies have shown the impact of smoking habit on platelet reactivity; with a reduction on platelet aggregation. Wether this inhibition in platelet reactivity is due to tobacco effects in platelet signaling pathways or due to a pharmacodynamic interaction with antiplatelet therapies is not well stablished.
Purpose
Our aim was to study the influence of smoking habit in platelet reactivity and in the response to P2Y12 inhibitors.
Methods
Patients admitted in four tertiary care hospitals due to an acute coronary syndrome that undergone percutaneous coronary intervention (PCI) were consecutively and prospectively recruited. All the patients received dual antiplatelet therapy with aspirin and a P2Y12 inhibitor following current European Guidelines. Platelet function was assessed at day 1 and day 30 post-PCI by VerifyNow P2Y12, VASP (Vasodilator-stimulated phosphoprotein) y MEA (Multiple electrode aggregometry).
Results
A total of 1000 patients were enrolled, of whom 12 had to be excluded due to inaccurate processing of blood samples. 372 patients (37,6%) had smoking habit. Non-smoking patients showed higher prevalence of high blood pressure [423 (68.7%) vs 196 (52.7%)] and diabetes mellitus [213 (34.6%) vs 81 (21.8%)]. Smoking patients were younger [57.3 (9,6) years old vs 68.4 (11.1)], with higher incidence of acute coronary syndrome with ST segment elevation [184 patients (49,5%) vs 241 (39.1%), p<0,001]. There were no differences in platelet function at day 1. When analysing platelet function 30 days post-PCI, a lower inhibition of platelet reactivity in non-smoking patients as compared with smoking patients was observed in those treated with clopidogrel, with higher prevalence of clopidogrel-resistance in non-smoking patients (VerifyNow, 51,2% prevalence of high platelet reactivity in non-smoking patients vs 34,9% 30 days after PCI, p=0,023). On the other hand, smoking patients that received ticagrelor did not show any differences. Patients with smoking habit treated with prasugrel showed a lower response of borderline statistical significance.
Conclusion
Smoking habit was associated with a lower response to prasugrel of borderline significance, and with higher response to clopidogrel, according with previous studies suggesting a pharmacodynamics interaction between tobacco use and P2Y12 inhibitors.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Fondo de Investigaciones Sanitarias (FIS)
Collapse
Affiliation(s)
| | | | | | | | - L.M Lugo Gavidia
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - E Bernardo
- Hospital Clinico San Carlos, Madrid, Spain
| | | | | | | | | | - I Silva
- University Hospital Central de Asturias, Oviedo, Spain
| | - F Marin
- University Hospital Virgen de la Arrixaca, El Palmar, Spain
| | | | | | - J.L Ferreiro
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| |
Collapse
|
32
|
Bonilla Palomas J, Anguita-Sanchez M, Elola F, Bernal J, Fernandez-Perez C, Ruiz-Ortiz M, Jimenez-Navarro M, Bueno H, Cequier A, Marin F. Trends in hospitalization and in-hospital mortality of patients with heart failure in Spain. A population-based study (2003–2015). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is one of the most pressing current public health concerns. However, in Spain there is a lack of population data.
Purpose
To investigate trends in HF hospitalization and in-hospital mortality rates.
Methods
We conducted a retrospective observational study of patients discharged with the principal diagnosis of HF from The National Health System' acute hospitals during 2003–2015. The source of the data was the Minimum Basic Data Set of the Ministry of Health, Consumer and Social Welfare. We analyzed trends in hospital discharge rates for HF (discharge rates were weighted by age and gender) an in-hospital mortality. The risk-standardized in-hospital mortality ratio (RSMR) was defined as the ratio between predicted mortality (which individually considers the performance of the hospital where the patient is attended) and expected mortality (which considers a standard performance according to the average of all hospitals) multiplied by the crude rate of mortality. RSMR was calculated using a risk adjustment multilevel logistic regression models developed by the Medicare and Medicaid Services. Temporal trend during the observed period was modelled using Poisson regression analysis with year as the only independent variable. In this model, the incidence rate ratio (IRR) and their 95% confidence intervals (95% CI) was calculated.
Results
A total of 1 254 830 episodes of HF were selected. Throughout 2003–2015 the number of hospital discharges with principal diagnosis of HF increased by 61% (IRR: 1.04; CI: 1.03–1.04; p<0.001), meanwhile the crude mortality rate and the mean length of stay (LOS) diminished significantly (IRR: 0.99; CI: 0.98–1; and IRR: 1.04; CI: 0.99–0.99; p<0.001, for both). Discharge rates weighted by age and sex showed a statistically significant increase during the period (IRR: 1.03; CI: 1.03–1.03; p<0.001); however, whereas discharge rates increased significantly in older groups of age (≥75 years old) (IRR: 1–1.02; p<0.001) they diminished in younger groups of age (45–74 years old) (IRR: 0.99; p<0.001 and there was not a significant trend in the discharge rates for the group of 35–44 years old (Figure). The risk-standardized in-hospital mortality ratio did not significantly change throughout 2003–2015 (IRR: 0.997; CI: 0.992–1; p=0.32), however the risk-standardized LOS ratio diminished from 1.07 in 2003 to 0.97 in 2015 (IRR: 0.98: IC: 0.98–0.99; p<0.001).
Conclusions
From 2003 to 2015, HF admission rate increased significantly in Spain as a consequence of the sustained increase of hospitalization in the population over 75. The crude in-hospital mortality rate diminished significantly for the same period, but the risk-standardized in-hospital mortality ratio did not significantly change.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | | | - F.J Elola
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - J.L Bernal
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - C Fernandez-Perez
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - M Ruiz-Ortiz
- Hospital Universitario Reina Sofía, Cόrdoba, Spain
| | | | - H Bueno
- University Hospital 12 de Octubre, Madrid, Spain
| | - A Cequier
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| |
Collapse
|
33
|
Bonilla Palomas J, Anguita-Sanchez M, Elola F, Bernal J, Fernandez-Perez C, Ruiz-Ortiz M, Jimenez-Navarro M, Bueno H, Cequier A, Marin F. Impact of hospital volume on in-hospital mortality and 30-day cardiac readmission of hospitalized patients with heart faliure. A population based study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is a major health care problem. Epidemiological data from hospitalized patients are scarce and the association between hospital volume and patient outcomes is largely unknown.
Purpose
The aim of this study was to analyze the relationship between hospital volume and outcomes (in-hospital mortality and 30-day cardiac readmission).
Methods
We conducted an observational study of patients discharged with the principal diagnosis of HF from The National Health System' acute hospitals during 2015. The source of the data was the Minimum Basic Data Set of the Ministry of Health, Consumer and Social Welfare. We calculated risk-standardized mortality rates (RSMR) at the index episode and risk-standardized cardiac diseases readmissions rates (RSRR) within 30 days after discharge by using a risk adjustment multilevel logistic regression models developed by the Medicare and Medicaid Services. Information on the number of HF discharges at each hospital in 2015 was analysed to classify centres into 2 categories (high- and low-volume hospitals). To discriminate between high- and low-volume centers, a K-means clustering algorithm was used. The association between volume and RSMR or RSRR was tested with the Pearson correlation coefficient and linear regression models.
Results
A total of 117 233 episodes of HF were selected during 2015. The mean age was 80±10 years and 46% were women. The crude in-hospital mortality rate was 12.1% and 30-day cardiac readmission rate was 18%. The cut-off point was set at 517 HF discharges per hospital during 2015. High volume hospitals had a statistically lower RSMR (10.3±2.8 vs 11.3±3.6; p<0.001) and higher RSRR (10.7±1.9 vs 9.2±1.6; p<0.001) than low volume hospitals. Low-volume hospitals showed higher dispersion of outcomes than high-volume, both for RSMR and RSRR (Figure).
Conclusions
We found that patients hospitalized for HF in 2105 had lower in-hospital mortality if they were admitted to a high-volume hospital. We have also found that high-volume hospitals had higher 30-day cardiac readmission rates.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | | | - F.J Elola
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - J.L Bernal
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - C Fernandez-Perez
- Fundaciόn Instituto para la Mejora de la Asistencia Sanitaria, Madrid, Spain
| | - M Ruiz-Ortiz
- Hospital Universitario Reina Sofía, Cόrdoba, Spain
| | | | - H Bueno
- University Hospital 12 de Octubre, Madrid, Spain
| | - A Cequier
- Hospital Universitari de Bellvitge, Barcelona, Spain
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| |
Collapse
|
34
|
Playan Escribano J, Vivas Balcones D, Lugo Gavidia L, Gomez Polo J, Marcano Fernandez A, Bernardo E, Ortega M, De La Hera Galarza J, Tello-Montoliu A, Besteiro Vazquez A, Silva I, Marin F, Roldan I, Gomez-Hospital J, Ferreiro J. Is “one size fits all” anti-aggregation really effective? Variability in the response to P2Y12 receptor inhibitors in obese patients. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Different “ex vivo” studies have shown both a greater platelet activation and higher rates of resistance to clopidogrel in obese patients. Although there is less evidence, less prasugrel activity has also been observed in these patients. Our aim was to study the variability of the response to clopidogrel, ticagrelor and prasugrel in obese patients, defined as a body mass index ≥30.
Methods
Prospective, multicenter, observational, pharmacodynamic study, conducted in a Spanish population of patients with an acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and double anti-aggregation with acetylsalicylic acid and a P2Y12 receptor inhibitor. Platelet function tests were performed the morning after the ICP and 30 days after it, including: 1) VerifyNow P2Y12 assay; 2) multiple electrode aggreometry (Multiplate); and 3) VASP analysis.
Results
Of the total patients included (988), 300 were obese (30.3%). The obese group was younger (62.8±12 years vs 64.9±12), had a higher incidence of arterial hypertension (76.3% vs. 56.7%), diabetes mellitus (35% vs. 27.5%); and lower incidence of chronic kidney disease (7.7% vs. 17%). There were no differences in the acute phase (day 1 after PCI) in the pharmacodynamic response to any of the P2Y12 inhibitors used. After 30 days, greater platelet aggregation (decreased response) was documented in obese patients treated with prasugrel according to VASP tests (PRI in non-obese 23.9±13% vs. 30.4±14.7% in obese, p 0.035) and MEA (area under the aggregation units curve in non-obese 251.7±104.1 vs 320±166.7 in obese, p 0.007) and a numerical trend with VerifyNow. A trend in the same direction was also observed in patients treated with clopidogrel that did not reach statistical significance with all the platelet function tests used. No differences were observed in the ticagrelor group.
Conclusion
Obese patients with an ACS treated with PCI have a worse response to thienopyridines than non-obese patients in the maintenance phase of antiaggregant treatment, while the response to ticagrelor is not affected by obesity. Completing the clinical follow-up proposed by the registry is necessary to know if these differences have an implication in cardiovascular events.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Fondo de Investigaciones Sanitarias (FIS)
Collapse
Affiliation(s)
| | | | | | | | | | - E Bernardo
- Hospital Clinico San Carlos, Madrid, Spain
| | - M.A Ortega
- Hospital Clinico San Carlos, Madrid, Spain
| | | | | | | | - I Silva
- University Hospital Central de Asturias, Oviedo, Spain
| | - F Marin
- University Hospital Virgen de la Arrixaca, El Palmar, Spain
| | - I Roldan
- University Hospital La Paz, Madrid, Spain
| | | | - J.L Ferreiro
- Hospital Universitari de Bellvitge, Barcelona, Spain
| |
Collapse
|
35
|
Rivera-Caravaca J, Roldan V, Vicente V, Lip G, Marin F. Relationship of particular matter and temperature on the risk of adverse events in atrial fibrillation patients. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Ambient particulate matter (PM), is a principal component of air pollutant and the main culprit of the adverse effects of air pollution on humans' health. In particular, PM with aerodynamic diameter <10 μm (PM10) has been shown to be associated with worse clinical outcomes. Similarly, cardiovascular risk increases during colder temperatures/seasons. Thus, both, air pollution and temperature fluctuations are examples confirming how the climate change is affecting our health. However, our knowledge about the impact of air pollution and temperature in anticoagulated atrial fibrillation (AF) patients is scarce.
Purpose
Herein, we investigated if PM10 and temperature are associated with an increased risk of adverse clinical outcomes in patients with AF taking vitamin K antagonists (VKAs).
Methods
We included AF patients who were stable on VKAs (INR 2.0–3.0) for 6 months in a tertiary hospital (Murcia, South-east Spain). During a median follow-up of 6.5 (IQR 4.3–7.9) years, ischemic strokes, major bleeds, adverse cardiovascular events, and mortality were recorded. From 2007–2016, data on average temperature and PM10 (PM with aerodynamic diameter <10 μm) were obtained and related to clinical outcomes.
Results
1361 patients (48.7% male; median age 76, IQR 71–81 years) were included. High PM10 and low temperatures were associated with higher risk of major bleeding (adjusted Hazard Ratio, aHR 1.44, 95% CI 1.22–1.70 and aHR 1.03, 95% CI 1.01–1.05) and mortality (aHR 1.50, 95% CI 1.34–1.69 and aHR 1.04, 95% CI 1.02–1.06) (Table 1). PM10 was also significantly associated with ischemic stroke and temperature with cardiovascular events. The relative risk for cardiovascular events and mortality increased in months in the lower quartile (Q1) of temperature (<12.74°C) (RR 1.12, 95% CI 1.04–1.21 and RR 1.41, 95% CI 1.15–1.74; respectively). Comparing seasons, there were higher risks of cardiovascular events in spring, autumn, and winter than in summer, whereas the risk of mortality increased only in winter.
Conclusions
In AF patients taking VKAs highPM10 and low temperature were associated with an increased the risk of ischemic stroke and cardiovascular events, respectively. Both factors increased major bleeding and mortality risks, which were higher during colder months and seasons.
Table 1. Univariate and Multivariate Cox
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- J.M Rivera-Caravaca
- Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Department of Cardiology, Murcia, Spain
| | - V Roldan
- University Hospital Morales Meseguer, Department of Hematology and Clinical Oncology, Murcia, Spain
| | - V Vicente
- University Hospital Morales Meseguer, Department of Hematology and Clinical Oncology, Murcia, Spain
| | - G.Y.H Lip
- Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
| | - F Marin
- Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Department of Cardiology, Murcia, Spain
| |
Collapse
|
36
|
Marin F, Rivera-Caravaca J, Roldan-Rabadan I, Perez Cabeza A, Garcia Seara J, Bertomeu-Gonzalez V, Leal M, Garcia-Fernandez A, Tercedor Sanchez L, Ayarra M, Ciudad M, Castano S, Maestre A, Anguita M, Garcia Bolao I. Spanish cohort profile, antithrombotic therapy and clinical outcomes at 1 year in the EORP atrial fibrillation long-term registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is associated with a high risk of stroke and mortality. Some years ago, the EURObservational Research Programme launched the General Long-Term Registry with the aim to evaluate contemporary management of AF patients in Europe, the current use of vitamin K antagonists (VKAs), direct-acting oral anticoagulants (DOACs) and other AF treatments, in relation to guideline recommendations.
Purpose
The present report aims to describe the characteristics of a large database on the management of AF in Spain, using the Spanish cohort included in the EORP-AF Long-Term Registry.
Methods
The EORP-AF Long-Term General Registry is a prospective, observational, large-scale multicentre registry sponsored and conducted by the ESC, enrolling AF patients in current cardiology practices in 250 centres from 27 participating ESC countries. Patients were enrolled consecutively when presenting with AF as primary or secondary diagnosis to inpatients and outpatient cardiology services from October 2013 to September 2016. The first Spanish patient in the EORP-AF Long-Term Registry was included in 2014. Initially, the aim was to carry out a follow-up up to 3 years but this was reduced to 2 years by the Executive Committee. To date, only data from the first year of follow-up is available for the Spanish cohort.
Results
A cohort of 729 AF Spanish patients was included (57.1% male, median age 75 [IQR 67–81] years, median CHA2DS2-VASc and HAS-BLED of 3 [IQR 2–5] and 2 [IQR 1–2], respectively). A relatively low proportion of patients (634, 87%) received oral anticoagulants (OACs), of which 389 (53.4%) were on VKAs and 245 (33.6%) were on DOACs (rate ratio = 1.59 [95% CI 1.35–1.87], p<0.001). Importantly, there were 98 (13.4%) patients taking concomitantly antiplatelet therapy and OACs; as well as 5.5% of patients were taking parenteral anticoagulation or antiplatelets alone. After 1 year, the proportion of patients on OACs increased from 87.0% to 88.1%. The proportion of DOACs users increased from 33.6% at baseline to 39.9%, partly due to switches from VKA to DOACs in relation to poor time in therapeutic range. At the same time, 34 (4.7%) patients withdrew OACs. During the first year of follow-up, 48 patients (6.6%) died, 7 (1.0%) suffered ischemic strokes and 6 (0.8%) transient ischemic attacks. Of note, there was a substantial rate of major bleeds (ISTH criteria) (57, 7.8%), of which 10 (1.4%) were intracranial haemorrhages.
Conclusions
Baseline data of the Spanish cohort are similar to that reported for the whole EORP cohort, including similar stroke and bleeding risks. OAC use slightly increased at 1-year, with low discontinuation rates which could be related with a low incidence of thromboembolic events. However, despite the ∼8% rate of major bleeding in overall, the use of a safer therapy such as DOACs is still low compared to VKAs, being the antiplatelets commonly used concomitantly with OACs
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Unconditional grant by Boehringer-Ingelheim
Collapse
Affiliation(s)
- F Marin
- Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Department of Cardiology, Murcia, Spain
| | - J Rivera-Caravaca
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - I Roldan-Rabadan
- Hospital Universitario La Paz, Department of Cardiology, Madrid, Spain
| | - A Perez Cabeza
- Hospital de Alta Resoluciόn de Benalmadena, Department of Cardiology, Benalmadena, Spain
| | - J Garcia Seara
- Hospital Clinico Universitario Santiago de Compostela, Department of Cardiology, Santiago de Compostela, Spain
| | - V Bertomeu-Gonzalez
- University Hospital San Juan de Alicante, Department of Cardiology, Alicante, Spain
| | - M Leal
- Health Center of San Andrés, Murcia, Spain
| | - A Garcia-Fernandez
- Hospital General Universitario de Alicante, Department of Cardiology, Alicante, Spain
| | - L Tercedor Sanchez
- University Hospital Virgen de las Nieves, Department of Cardiology, Granada, Spain
| | - M Ayarra
- Huarte Primary Care Center, Pamplona, Spain
| | - M Ciudad
- University Hospital De La Princesa, Department of Internal Medicine, Madrid, Spain
| | - S Castano
- Hospital Nuestra Señora del Prado, Department of Cardiology, Toledo, Spain
| | - A Maestre
- Hospital Vinalopo Salud, Department of Internal Medicine, Elche, Spain
| | - M Anguita
- University Hospital Reina Sofia, Department of Cardiology, Cordoba, Spain
| | - I Garcia Bolao
- University of Navarra Clinic, Department of Cardiology, Pamplona, Spain
| |
Collapse
|
37
|
Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, Potpara T, Dan G, Kalarus Z, Tavazzi L, Maggioni A, Lip G. Impact of body mass index on outcomes in European patients with atrial fibrillation: the ESC EHRA EORP Atrial Fibrillation General Long-Term registry (AFGen LT). Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
The impact of body mass index (BMI) on outcomes in patients with atrial fibrillation (AF) has been largely debated.
Aims
To describe the relationship between BMI categories and clinical outcomes in a large cohort of European AF patients.
Methods
We included all AF patients with available baseline BMI and creatinine clearance and 1-year follow-up data enrolled in the EORP-AF General Long-Term Registry. Outcomes considered were: i) a composite of any thromboembolic event (TE)/acute coronary syndrome (ACS)/cardiovascular (CV) death; ii) CV death; iii) all-cause death.
Results
A total of 7,759 patients were included in this analysis. Of these, 55 (0.7%) were underweight, 2,074 (26.7%) were normal weight, 3,170 (40.9%) were overweight, 1,703 (21.9%) were obese and 757 (9.8%) were severe obese. Mean age was progressively lower across the categories (p<0.0001), with proportion of patients aged≥75 years also progressively lower (52.7% in underweight to 19.4% in severe obese patients; p<0.001). Both underweight (41.8%) and severe obese (25.0%) patients were more likely symptomatic (p<0.001). Mean CHA2DS2-VASc score was higher in underweight patients (p=0.0325). Use of any oral anticoagulant therapy was progressively higher across the BMI categories (p<0.001). At 1-year follow-up the rate of all outcomes considered were highest for underweight patients and lowest in severe obese [Figure 1]. On univariate Cox regression analysis, being underweight was consistently associated to a higher risk for all outcomes, while increasing of weight categories was associated with progressively lower risk for adverse outcomes. After full adjustment with clinical and pharmacological characteristics, no effect of higher BMI classes was found for any outcome, but an independent association with an increased risk of CV death and all-cause death was seen for underweight patients (Table 1).
Conclusions
In a large cohort of European AF patients a progressively lower rate of outcomes was found across increasing BMI classes. After full adjustments, no significant association was found between the higher BMI classes and outcomes. Underweight was associated with an increased risk for CV death and all-cause death.
Figure 1. Outcomes at 1-year Follow-up
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Since the start of EORP programme, several companies have supported it with unrestricted grants
Collapse
Affiliation(s)
- G Boriani
- University of Modena & Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy
| | | | - C Laroche
- European Society of Cardiology, EURObservational Research Programme Department, Sophia-Antipolis, France
| | - L Fauchier
- University Hospital of Tours, Cardiology Department, Tours, France
| | - F Marin
- University of Murcia, Cardiology Department, Murcia, Spain
| | - M Nabauer
- Ludwig-Maximilians University, Cardiology Department, Munich, Germany
| | - T Potpara
- Clinical center of Serbia, Cardiology Department, Belgrade, Serbia
| | - G.A Dan
- Colentina University Hospital, Bucharest, Romania
| | - Z Kalarus
- Silesian Center for Heart Diseases (SCHD), Zabrze, Poland
| | - L Tavazzi
- Maria Cecilia Hospital, Cotignola, Italy
| | | | - G.Y.H Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
| |
Collapse
|
38
|
Vitolo M, Proietti M, Harrison S, Fauchier L, Marin F, Potpara T, Lane D, Boriani G, Lip G. Temporal changes in quality of life amongst European atrial fibrillation patients: relationship to all-cause mortality. A report from the ESC-EHRA EORP-AF General Long-Term Registry. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) significantly impacts on patients' quality of life (QoL). An impaired QoL has been associated with worse outcomes even in AF patients, but contemporary data in a large-scale pan-European population are limited.
Purpose
We aimed to assess temporal changes in AF patients' QoL across 2 years follow-up observation, and the relationship of QoL changes with all-cause death.
Methods
We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. The EQ-5D-5L questionnaire was used to assess QoL. A Health Utility Score (HUS), indicating the overall health state (1 equals perfect health), was derived. Differences throughout the follow-up (Baseline, 1-Y FU, 2-Y FU) observation were assessed. The study outcome was all-cause mortality.
Results
Out of a total of 11906 patients, 8097 (73.0%) were available for this analysis. Mean (SD) age was 69.1 (11.5) years; 60.8% males; median CHA2DS2-VASc and HASBLED scores were 3 (IQR 2–4) and 1 (1–2), respectively. The mean (SD) HUS at baseline was 0.815 (0.200) and 0.834 (0.196), 0.829 (0.195) at 1-year follow-up and 2-year follow-up, respectively (p<0.0001 for changes over time). Patients with a higher CHA2DS2-VASc score (CHA2DS2-VASc 6–9) reported a significant reduction in the quality of life, compared to the other CHA2DS2-VASc strata, with a mean (SD) HUS decreasing from 0.754 (0.214) at baseline to 0.727 (0.238) at 2-year follow-up (F=6.538, p<0.0001) (Figure). Multivariate analysis demonstrated that age [−0.001 (95% CI [−0.002, −0.121]) and coronary artery disease (CAD) [−0.016 (95% CI [−0.029, −0.004] were independently inversely associated with increasing QoL. Positive changes in HUS over time were inversely associated with an increase in the risk of all-cause death, even after adjusting for chronic kidney disease, liver disease, chronic obstructive pulmonary disease, oral anticoagulants and type of AF (OR:0.24, 95% CI: 0.13–0.45 for increasing HUS difference, as a continuous variable).
Conclusions
In a contemporary European-wide cohort of AF patients, significant temporal changes in QoL were found. Patients at higher stroke risk according to CHA2DS2-VASc score showed a significant reduction in the QoL. Age and CAD were independently associated with changes in QoL. A greater reduction in HUS (i.e. worsening QoL) over time was associated with a higher risk of all-cause death.
Temporal changes in HUS
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Since the start of EORP, several companies have supported the programme with unrestricted grants
Collapse
Affiliation(s)
- M Vitolo
- University of Modena & Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy
| | - M Proietti
- University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy
| | - S Harrison
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
| | - L Fauchier
- University Hospital of Tours, Service de Cardiologie, Tours, France
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Department of Cardiology, Univeristy of Murcia, Murcia, Spain
| | - T Potpara
- University Belgrade Medical School, Belgrade, Serbia
| | - D.A Lane
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
| | - G Boriani
- University of Modena & Reggio Emilia, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy
| | - G.Y.H Lip
- University of Liverpool, Liverpool Centre for Cardiovascular Science, Liverpool, United Kingdom
| |
Collapse
|
39
|
Body JJ, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. Efficacy of teriparatide compared with risedronate on FRAX ®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int 2020; 31:1935-1942. [PMID: 32474650 PMCID: PMC7497508 DOI: 10.1007/s00198-020-05463-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 05/11/2020] [Indexed: 11/29/2022]
Abstract
UNLABELLED FRAX® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FRAX®-defined MOF compared with those treated with risedronate. INTRODUCTION The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX®-defined major osteoporotic fractures (MOF), which include clinical vertebral, hip, humerus, and forearm fractures. METHODS In total, 1360 postmenopausal women (mean age 72.1 years) were randomized to receive subcutaneous daily teriparatide (20 μg) or oral weekly risedronate (35 mg). Patient cumulative incidence of ≥ 1 FRAX®-defined MOF and of all clinical fractures were estimated by Kaplan-Meier analyses, and the comparison between treatments was based on the stratified log-rank test. Additionally, an extended Cox model was used to estimate HRs at different time points. Incidence fracture rates were estimated at each 6-month interval. RESULTS After 24 months, 16 (2.6%) patients in the teriparatide group had ≥ 1 low trauma FRAX®-defined MOF compared with 40 patients (6.4%) in the risedronate group (HR 0.40; 95% CI 0.23-0.68; p = 0.001). Clinical vertebral and radius fractures were the most frequent FRAX®-defined MOF sites. The largest difference in incidence rates of both FRAX®-defined MOF and all clinical fractures between treatments occurred during the 6- to 12-month period. There was a statistically significant reduction in fractures between groups as early as 7 months for both categories of clinical fractures analyzed. CONCLUSION In postmenopausal women with severe osteoporosis, treatment with teriparatide was more efficacious than risedronate, with a 60% lower risk of FRAX®-defined MOF during the 24-month treatment period. Fracture risk was statistically significantly reduced at 7 months of treatment. CLINICAL TRIAL INFORMATION ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.
Collapse
Affiliation(s)
- J-J Body
- CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
| | - F Marin
- Lilly Research Center Europe, Madrid, Spain
| | - D L Kendler
- University of British Columbia, Vancouver, Canada
| | - C A F Zerbini
- Centro Paulista de Investigaçao Clínica, Sao Paulo, Brazil
| | | | - R Möricke
- Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany
| | - E Casado
- University Hospital Parc Taulí Sabadell, Barcelona, Spain
| | - A Fahrleitner-Pammer
- Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
| | - J J Stepan
- Institute of Rheumatology and Faculty of Medicine 1, Charles University, Prague, Czech Republic
| | | | | | - P Geusens
- Maastricht University Medical Center, Maastricht, The Netherlands
| |
Collapse
|
40
|
Lerebours A, Marin F, Bouvier S, Egles C, Rassineux A, Masquelet AC. Trends in Trapeziometacarpal Implant Design: A Systematic Survey Based on Patents and Administrative Databases. J Hand Surg Am 2020; 45:223-238. [PMID: 31987639 DOI: 10.1016/j.jhsa.2019.11.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 07/09/2019] [Accepted: 11/15/2019] [Indexed: 02/02/2023]
Abstract
Hand function is inseparably linked to the condition of the thumb. The trapeziometacarpal (TMC) joint that provides the different movements of opposition is one of the joints most affected by osteoarthritis, which causes an irreversible deformation of the bone. The ideal thumb carpometacarpal implant must restore range of movement, prevent complications, be biocompatible, and have good mechanical properties (ie, low wear, high corrosion resistance, and osteointegration properties where it is anchored in a bone). The integrity of the implant and the surrounding biological structures must be long-lasting and withstand constant stresses induced by the prosthesis. Three main types of implant systems for the thumb are currently clinically available; others are under investigation in human subjects. This systematic review is based on administrative databases, patents, the literature, and information from orthopedic companies. It provides a summary of strategies and design changes and an overview of the biomechanical characteristics of currently available carpometacarpal implants for treating osteoarthritis of the thumb.
Collapse
Affiliation(s)
- Augustin Lerebours
- CNRS, FRE2012 Laboratory Roberval, Sorbonne Universities Alliance, University of Technology of Compiègne, Compiègne, France.
| | - Frederic Marin
- CNRS, UMR7338 Laboratory, Biomechanics and Bioengineering, Sorbonne Universities Alliance, University of Technology of Compiègne, Compiègne, France
| | - Salima Bouvier
- CNRS, FRE2012 Laboratory Roberval, Sorbonne Universities Alliance, University of Technology of Compiègne, Compiègne, France
| | - Christophe Egles
- Department of Orthopedics, Trauma, and Hand Surgery, Saint Antoine Hospital, Paris, France
| | - Alain Rassineux
- CNRS, FRE2012 Laboratory Roberval, Sorbonne Universities Alliance, University of Technology of Compiègne, Compiègne, France
| | | |
Collapse
|
41
|
Chowdhury A, Vezio P, Bonaldi M, Borrielli A, Marino F, Morana B, Prodi GA, Sarro PM, Serra E, Marin F. Quantum Signature of a Squeezed Mechanical Oscillator. Phys Rev Lett 2020; 124:023601. [PMID: 32004051 DOI: 10.1103/physrevlett.124.023601] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Indexed: 06/10/2023]
Abstract
Recent optomechanical experiments have observed nonclassical properties in macroscopic mechanical oscillators. A key indicator of such properties is the asymmetry in the strength of the motional sidebands produced in the probe electromagnetic field, which is originated by the noncommutativity between the oscillator ladder operators. Here we extend the analysis to a squeezed state of an oscillator embedded in an optical cavity, produced by the parametric effect originated by a suitable combination of optical fields. The motional sidebands assume a peculiar shape, related to the modified system dynamics, with asymmetric features revealing and quantifying the quantum component of the squeezed oscillator motion.
Collapse
Affiliation(s)
- A Chowdhury
- CNR-INO, L.go Enrico Fermi 6, I-50125 Firenze, Italy
| | - P Vezio
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Carrara 1, I-50019 Sesto Fiorentino (FI), Italy
| | - M Bonaldi
- Institute of Materials for Electronics and Magnetism, Nanoscience-Trento-FBK Division, 38123 Povo, Trento, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Trento Institute for Fundamental Physics and Application, I-38123 Povo, Trento, Italy
| | - A Borrielli
- Institute of Materials for Electronics and Magnetism, Nanoscience-Trento-FBK Division, 38123 Povo, Trento, Italy
- Istituto Nazionale di Fisica Nucleare (INFN), Trento Institute for Fundamental Physics and Application, I-38123 Povo, Trento, Italy
| | - F Marino
- CNR-INO, L.go Enrico Fermi 6, I-50125 Firenze, Italy
- INFN, Sezione di Firenze, Via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
| | - B Morana
- Institute of Materials for Electronics and Magnetism, Nanoscience-Trento-FBK Division, 38123 Povo, Trento, Italy
- Dept. of Microelectronics and Computer Engineering /ECTM/DIMES, Delft University of Technology, Feldmanweg 17, 2628 CT Delft, Netherlands
| | - G A Prodi
- Istituto Nazionale di Fisica Nucleare (INFN), Trento Institute for Fundamental Physics and Application, I-38123 Povo, Trento, Italy
- Dipartimento di Fisica, Università di Trento, I-38123 Povo, Trento, Italy
| | - P M Sarro
- Dept. of Microelectronics and Computer Engineering /ECTM/DIMES, Delft University of Technology, Feldmanweg 17, 2628 CT Delft, Netherlands
| | - E Serra
- Istituto Nazionale di Fisica Nucleare (INFN), Trento Institute for Fundamental Physics and Application, I-38123 Povo, Trento, Italy
- Dept. of Microelectronics and Computer Engineering /ECTM/DIMES, Delft University of Technology, Feldmanweg 17, 2628 CT Delft, Netherlands
| | - F Marin
- CNR-INO, L.go Enrico Fermi 6, I-50125 Firenze, Italy
- European Laboratory for Non-Linear Spectroscopy (LENS), Via Carrara 1, I-50019 Sesto Fiorentino (FI), Italy
- INFN, Sezione di Firenze, Via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
- Dipartimento di Fisica e Astronomia, Università di Firenze, Via Sansone 1, I-50019 Sesto Fiorentino (FI), Italy
| |
Collapse
|
42
|
Kim YY, Darkins R, Broad A, Kulak AN, Holden MA, Nahi O, Armes SP, Tang CC, Thompson RF, Marin F, Duffy DM, Meldrum FC. Hydroxyl-rich macromolecules enable the bio-inspired synthesis of single crystal nanocomposites. Nat Commun 2019; 10:5682. [PMID: 31831739 PMCID: PMC6908585 DOI: 10.1038/s41467-019-13422-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 11/05/2019] [Indexed: 11/24/2022] Open
Abstract
Acidic macromolecules are traditionally considered key to calcium carbonate biomineralisation and have long been first choice in the bio-inspired synthesis of crystalline materials. Here, we challenge this view and demonstrate that low-charge macromolecules can vastly outperform their acidic counterparts in the synthesis of nanocomposites. Using gold nanoparticles functionalised with low charge, hydroxyl-rich proteins and homopolymers as growth additives, we show that extremely high concentrations of nanoparticles can be incorporated within calcite single crystals, while maintaining the continuity of the lattice and the original rhombohedral morphologies of the crystals. The nanoparticles are perfectly dispersed within the host crystal and at high concentrations are so closely apposed that they exhibit plasmon coupling and induce an unexpected contraction of the crystal lattice. The versatility of this strategy is then demonstrated by extension to alternative host crystals. This simple and scalable occlusion approach opens the door to a novel class of single crystal nanocomposites.
Collapse
Affiliation(s)
- Yi-Yeoun Kim
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK.
| | - Robert Darkins
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, UK
| | - Alexander Broad
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, UK
| | - Alexander N Kulak
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| | - Mark A Holden
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| | - Ouassef Nahi
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| | - Steven P Armes
- Department of Chemistry, University of Sheffield, Brook Hill, Sheffield, S3 7HF, UK
| | - Chiu C Tang
- Diamond Light Source, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, UK
| | - Rebecca F Thompson
- The Astbury Biostructure Laboratory, Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK
| | - Frederic Marin
- UMR CNRS 6282 Biogeosciences, Université de Bourgogne-Franche-Comté, 6 Boulevard Gabriel, 21000, Dijon, France
| | - Dorothy M Duffy
- Department of Physics and Astronomy, University College London, Gower Street, London, WC1E 6BT, UK.
| | - Fiona C Meldrum
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK.
| |
Collapse
|
43
|
Boucard A, Marin F, Monternier PA, Brand M, Le Grand B. P4607A specific complex I-induced ROS modulator, OP2113, is a new cardioproctective agent against acute myocardial infarction injuries during reperfusion. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0990] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Hospital death rates due to myocardial infarction are still a concern and heart failure occurs in nearly a quarter of older patients who present with ST elevation myocardial infarction. Novel therapies are thus desperately needed to reduce infarct size to preserve left ventricular function and to prevent the onset of heart failure.
Purpose
OP2113, trithio-p-methoxyphenylpropene (anethole trithione, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione, anethole dithionethiol), a potential suppressor of complex I superoxide/hydrogen peroxide (ROS) production was evaluated in a sheep model of regional ischemia in order to demonstrate cardioprotective properties against infarct size and left ventricular function remodeling.
Methods
A series of experiments was performed in vitro on isolated mitochondria and on C2C12 cells to clarify the mechanism of action and to test whether OP2113 impacts biological variables of mitochondria. In vivo, anesthetized sheep underwent 60 min ischemia and 120 min reperfusion and either received OP2113 (1–5 μg/kg, i.v at start of and for the duration of the reperfusion) or the vehicle. The animals underwent then a 3-day follow-up period until euthanasia. Ischemic biomarkers, troponin I, CPK, and ventricular function through echocardiography were quantified during reperfusion and infarct size through histological analysis.
Results
OP2113 reduced ROS production from site IQ in mitochondria isolated from rat skeletal muscle, with IC50 of 26±1.4 μM (n=3). It is specific; IC50 values for other sites are at least 15-fold higher (site IIIQo – 414 μM; site IIF – 582 μM; sites IF/DH, PF, GQ >5 mM). Furthermore, OP2113 did not affect oxidative phosphorylation, respiration or growth of C2C12 cells. In the sheep model, OP2113 (1–10 μg/kg) dose-dependently prevented reperfusion-induced ST segment increase during the first minutes. When OP2113 plasmatic concentration was superior to 1 ng/mL (generally associated with a threshold dose of 5 μg/kg), troponin Ic levels measured over the experiment was strongly decreased and the cardiac function significantly improved (+86%), when compared to the vehicle group (left panel). Finally, the infarct size was diminished by 57% comparing to the vehicle group (10.3% vs 23.8%, respectively, right panel).
Conclusion
In a large animal model of ischemia-reperfusion, OP2113 with very low infused dose, reduced ST segment elevation, reduced troponin release, improved left ejection fraction and reduced infarct size. Collectively, these results demonstrate that OP2113, through a new mechanism of action, is a potent cardioprotective compound.
Collapse
Affiliation(s)
| | - F Marin
- OP2 Drugs, Bordeaux-Pessac, France
| | - P A Monternier
- Buck Institute for Research on Aging, Novato, United States of America
| | - M Brand
- Buck Institute for Research on Aging, Novato, United States of America
| | | |
Collapse
|
44
|
Anguita M, Sambola Ayala A, Elola J, Bernal JL, Fernandez C, Ferreiro JL, Bueno H, Marin F, Bonilla JL, Nunez-Villota J, Sanmartin M, Raposeiras S, Jimenez-Navarro MF, Filgueiras D, Ruiz-Ortiz M. P1515Female sex is an independent predictor of mortality in patients with STEMI in Spain: a study in 325,017 episodes over 11 years (2005–2015). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recent studies reported a decrease in the mortality of ST-elevation myocardial infarction (STEMI) patients. This favorable evolution could not extend to women. The interaction between gender and mortality in STEMI remains controversial.
Purpose
To assess the impact of female sex on mortality of patients with STEMI through of period of 11 years.
Methods
We conducted a retrospective longitudinal study using information provided by the minimal database system of the Spanish National Health System to identify all hospitalizations in patients aged 35–94 years with the principal diagnosis of STEMI from 2005–2015.
Results
A total of 325,017 STEMI were identified. Of them, 273,182 were included, and 106,277 (38.8%) were women. Women were older than men and had more comorbidities. Through the study period 53% men vs 37.2% underwent PTCA; women presented more frequently heart failure, shock and stroke than men (p<0.001, respectively). The mean crude in-hospital mortality rate for the whole study period was higher in women (OR: 2.18; 95% CI: 2.12.-2.23, p<0.0001). Female sex was independently associated with higher in-hospital mortality (adjusted OR: 1.18; 95% CI: 1.14–1.22, p<0.001) (Table 1). The risk was maintained through the whole study period (lower OR: 1.14 in 2014; higher OR: 1.28 in 2006).
Table 1. Variables independently associated with in-hospital mortality adjusted by risk in a multilevel logistic regression model, 2005–2015 STEMI In-hospital mortality Odds Ratio P 95% CI Woman 1.18 <0.001 1.14 1.22 Age 1.06 <0.001 1.06 1.06 History of PTCA 1.58 <0.001 1.40 1.77 Congestive heart failure 1.26 <0.001 1.22 1.30 Acute Myocardial Infarction 1.84 <0.001 1.54 2.20 Anterior myocardial infarction 1.47 <0.001 1.23 1.76 Cardio-respiratory failure or shock 15.25 <0.001 14.78 15.75 Hypertension 0.81 <0.001 0.79 0.84 Stroke 5.76 <0.001 5.18 6.42 Cerebrovascular disease 0.86 <0.001 0.79 0.93 Renal failure 1.95 <0.001 1.88 2.02 Vascular disease and complications 7.03 <0.001 5.72 8.63 CI, Confidence Interval.
Conclusions
Female sex is an independent predictor of mortality in patients with STEMI in Spain, maintaining through a period of the 11 years.
Collapse
Affiliation(s)
- M Anguita
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| | | | - J Elola
- IMAS, Cardiology, Madrid, Spain
| | | | | | - J L Ferreiro
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - H Bueno
- University Hospital 12 de Octubre, Cardiology, Madrid, Spain
| | - F Marin
- Hospital Universitario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - J L Bonilla
- Hospital San Juan de la Cruz (Úbeda)., Cardiology, Cordoba, Spain
| | - J Nunez-Villota
- University Hospital Clinic of Valencia, Cardiology, Valencia, Spain
| | - M Sanmartin
- University Hospital Ramon y Cajal de Madrid, Cardiology, Madrid, Spain
| | - S Raposeiras
- Complejo Hospitalario Universitario de Vigo., Cardiology, Vigo, Spain
| | | | - D Filgueiras
- Hospital Clinic San Carlos, Cardiology, Madrid, Spain
| | - M Ruiz-Ortiz
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| |
Collapse
|
45
|
Lugo Gavidia L, Vivas D, De La Hera JM, Tello-Montoliu A, Marcano AL, Besteiro A, Silva I, Gomez-Polo JC, Playan J, Gomez-Hospital JA, Cequier A, Marin F, Roldan I, Ferreiro JL. 255Impact of the type of acute coronary syndrome on the pharmocodynamic response to P2Y12 inhibitors in the acute and maintenance phase of therapy. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The presence of an acute coronary syndrome (ACS) is per se a predictor of reduced responsiveness to clopidogrel; in particular, patients with ST-elevation myocardial infarction (STEMI) have impaired clopidogrel-induced platelet inhibition than those with other forms of ACS. However, the impact of the type of ACS on the pharmocodynamic efficacy of more potent P2Y12 antagonists such as prasugrel or ticagrelor has not been fully elucidated to date.
Purpose
To assess the impact of the type of ACS on platelet inhibition mediated by P2Y12 receptor antagonists in the acute and the maintenance phase of therapy in a contemporary cohort of ACS patients undergoing percutaneous coronary intervention (PCI).
Methods
Substudy of a prospective, national, multicentre, pharmacodynamic registry conducted in a population of ACS patients undergoing PCI and treated with dual antiplatelet therapy including aspirin and a P2Y12 inhibitor as per clinical indication. Patients were classified according to the ACS diagnosis into groups: a) STEMI, b) non-ST-elevation ACS (NSTEACS), c) unstable angina (UA), and d) other (excluded from the present analysis). Platelet function tests (PFT) were performed at day 1 and day 30 (±5) after PCI and included: 1) VerifyNow P2Y12 assay, expressed as P2Y12 reaction units (PRUs); 2) Vasodilator-stimulated phosphoprotein (VASP) assay; and 3) Multiple electrode aggregometry (MEA).
Results
A total of 965 patients (372 with STEMI, 395 with NSTEACS and 198 with UA) were included in the present substudy. At day 1, the proportions of patients with each type of ACS according to the P2Y12 inhibitor received were: 1) clopidogrel (n=317): STEMI 35.0%, NSTEACS 34.4% and UA 30.6%; 2) prasugrel (n=192): STEMI 70.3%, NSTEACS 17.7% and UA 12.0%; 3) ticagrelor (n=456): STEMI 27.6%, NSTEACS 55.3% and UA 17.1%. A statistically significant reduced platelet inhibition, measured with the VerifyNow system, was observed in STEMI patients compared with the other forms of ACS in patients receiving clopidogrel (STEMI: 217.3±8.1, NSTEACS: 157.1±7.9 and UA: 164.9±8.6 PRUs; p for STEMI vs. NSTEACS <0.001 and p for STEMI vs. UA <0.001) and ticagrelor (STEMI: 57.7±3.8, NSTEACS: 45.2.1±2.6 and UA: 40.6±4.9 PRUs; p for STEMI vs. NSTEACS 0.008 and p for STEMI vs. UA 0.007), while a numerical trend towards greater platelet reactivity in STEMI compared to UA was observed in subjects receiving prasugrel (Figure). Remarkably, at day 30, no significant differences on platelet inhibition were observed according to the ACS type with any of the P2Y12 inhibitors. Similar results were observed with MEA and VASP assays.
PD response according to the ACS type
Conclusions
Patients presenting with STEMI have impaired platelet inhibition mediated by P2Y12 antagonists compared to other types of ACS during the acute phase of therapy, whereas no difference is observed during the maintenance phase of treatment.
Acknowledgement/Funding
Funded by Instituto de Salud Carlos III through the project PI13/01012 (co-funded by European Regional Development Fund. ERDF, a way to build Europe)
Collapse
Affiliation(s)
- L Lugo Gavidia
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| | - D Vivas
- Hospital Clinic San Carlos, Department of Cardiology, Madrid, Spain
| | - J M De La Hera
- University Hospital Central de Asturias, Department of Cardiology, Oviedo, Spain
| | - A Tello-Montoliu
- University Hospital Virgen de la Arrixaca, Department of Cardiology, Murcia, Spain
| | - A L Marcano
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| | - A Besteiro
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| | - I Silva
- University Hospital Central de Asturias, Department of Cardiology, Oviedo, Spain
| | - J C Gomez-Polo
- Hospital Clinic San Carlos, Department of Cardiology, Madrid, Spain
| | - J Playan
- Hospital Clinic San Carlos, Department of Cardiology, Madrid, Spain
| | - J A Gomez-Hospital
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| | - A Cequier
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| | - F Marin
- University Hospital Virgen de la Arrixaca, Department of Cardiology, Murcia, Spain
| | - I Roldan
- University Hospital La Paz, Department of Cardiology, Madrid, Spain
| | - J L Ferreiro
- Bellvitge University Hospital - IDIBELL, Heart Diseases Institute, Hospitalet de Llobregat (L'), Spain
| |
Collapse
|
46
|
Vera Sainz A, Diez Villanueva P, Ariza Sole A, Formiga F, Lopez Palop R, Marin F, Vidan M, Martinez Selles M, Salamanca J, Sionis A, Garcia Pardo H, Bueno H, Sanchis J, Abu Assi E, Alfonso F. P6264Mitral regurgitation and prognosis after non-ST-segment elevation myocardial infarction in very old patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Mitral regurgitation (MR) after acute coronary syndromes is associated with adverse prognosis. However, the prognostic impact of MR in older patients with Non ST-segment Elevation Myocardial Infarction (NSTEMI) has not been well addressed.
Methods
The multicenter LONGEVO-SCA prospective registry included 532 unselected patients with NSTEMI aged ≥80 years. Echocardiography performed during admission quantified mitral valve parameters in 497 patients, who were classified according to mitral regurgitation (MR) status in two groups: significant (moderate or severe) or no significant MR (absent or mild). We evaluated the impact of MR status on mortality or readmission at 6-months.
Results
Mean age was 84.3±4.1 years, 308 (61.9%) were males. A total of 108 patients (21.7%) had significant MR. Compared with patients without significant MR these patients had lower systolic blood pressure (132±28 vs 141±27 mmHg), higher heart rate (82±21 vs 74±17 bpm), worse Killip class (≥II 49.5% vs 22.5%), lower ejection fraction (47±14% vs 55±11%), higher pulmonary pressure (42±15 vs 35±11 mmHg), as well as more frequent new onset atrial fibrillation (16.4% vs 7.2%) (all p values=0.001). Patients with significant MR also had higher in-hospital mortality (4.6% vs 1.3%, p=0.04) and longer hospital stay (median 8 [5–12] vs 6 [4–10] days, p=0.002),and higher mortality/readmission at 6 months (HR 1,54, 95% CI 1.09–2.18). However, after adjusting for potential confounders, this last association was not significant.
Conclusions
Significant MR is seen in about one fifth of octogenarians with NSTEMI. Patients with significant MR have a poor prognosis, which is mainly determined by their clinical characteristics.
Collapse
Affiliation(s)
- A Vera Sainz
- University Hospital De La Princesa, Madrid, Spain
| | | | - A Ariza Sole
- University Hospital of Bellvitge, Barcelona, Spain
| | - F Formiga
- University Hospital of Bellvitge, Barcelona, Spain
| | - R Lopez Palop
- University Hospital San Juan de Alicante, Alicante, Spain
| | - F Marin
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - M Vidan
- University Hospital Gregorio Maranon, Madrid, Spain
| | | | - J Salamanca
- University Hospital De La Princesa, Madrid, Spain
| | - A Sionis
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | - H Bueno
- University Hospital 12 de Octubre, Madrid, Spain
| | - J Sanchis
- University Hospital Clinic of Valencia, Valencia, Spain
| | | | - F Alfonso
- University Hospital De La Princesa, Madrid, Spain
| |
Collapse
|
47
|
Esteve Pastor MA, Ruiz-Nodar JM, Rivera-Caravaca JM, Sandin Rollan M, Lozano T, Vicente-Ibarra N, Orenes-Pinero E, Macias-Villanego MJ, Pernias-Escrig V, Carrillo-Aleman L, Candela E, Veliz-Martinez A, Tello-Montoliu A, Martinez-Martinez JG, Marin F. P3842One-year efficacy and safety of prasugrel and ticagrelor in patients with Acute Coronary Syndromes: results from a prospective and multicenter ACHILLES Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Prasugrel and Ticagrelor have demonstrated higher efficacy than clopidogrel in their main clinical trials for patients with Acute Coronary Syndrome (ACS). However, the long-term prognosis and different clinical characteristics related with the type of antiplatelet prescription in current clinical practice ACS patients have not been analyzed in depth.
Purpose
The objective of this study was to analyze the clinical profile of ACS and the efficacy and safety of new antiplatelet drugs (NAD) in current clinical practice patients discharged after an ACS.
Methods
We collected data from ACHILLES registry, and observational, prospective and multicenter registry of patients discharged after an ACS. We analyzed baseline characteristics, clinical profile and therapy during ACS admission and compared with the different treatments at discharge. After 1 year of follow-up, ischaemic and major bleeding events were analyzed. Multivariate Cox regression analysis and Kaplan Meier curves were also plotted.
Results
Of 1,717 consecutive patients, 1,294 (75.4%) were discharged with a P2Y12 inhibitor without oral anticoagulation. NAD was indicated in 47%. Patients treated with clopidogrel were elderly (69.1±13.4 vs. 60.4±11.5 years; p<0.001) and with a higher prevalence of cardiovascular risk factors. GRACE and CRUSADE score were higher in the clopidogrel than in NAD group (p<0.001). After 1 year of follow-up, 64 (5.0%/year) patients had a new myocardial infarction, 127 (10.0%/year) had a MACE and 78 (6.1%/year) patients died. Patients treated with clopidogrel had significantly higher annual rate of cardiovascular mortality, MACE and all cause-mortality (all of them p<0.001) without differences in major bleeding (p=0.587) compared with NAD therapy. After multivariate adjustment for the main clinical variables related with adverse prognosis in ACS patients, the discharge with NAD was independently associated with lower risk of all-cause mortality [HR 0.49, 95% CI (0.24–0.99); p=0.043] and lower risk of MACE [HR 0.65, 95% CI (0.43–0.99); p=0.049].
Event Free Survival according NAD Use
Conclusions
In this prospective, observational and current clinical practice ACS registry, the use of NAD was associated with a reduction of adverse events compared with clopidogrel in patients with ACS. NAD prescription at discharge was independently associated with lower all-cause mortality and MACE without differences in bleeding events. However, clopidogrel remained the most common P2Y12 inhibitor employed for ACS, especially in older and high risk population.
Collapse
Affiliation(s)
- M A Esteve Pastor
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - J M Ruiz-Nodar
- General University Hospital of Alicante, Alicante, Spain
| | - J M Rivera-Caravaca
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | | | - T Lozano
- General University Hospital of Alicante, Alicante, Spain
| | | | - E Orenes-Pinero
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | | | | | | | - E Candela
- General University Hospital of Alicante, Alicante, Spain
| | - A Veliz-Martinez
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - A Tello-Montoliu
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | | | - F Marin
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| |
Collapse
|
48
|
Soler Costa M, Nunez J, Ruiz V, Bonanad C, Formiga F, Valero E, Martinez Selles M, Marin F, Ruescas A, Garcia Blas S, Minana G, Abu-Assi E, Bueno H, Ariza-Sole A, Sanchis J. 5877Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The Charlson's is the most used comorbidity index. It comprises 19 comorbidities, some of which are infrequent in elderly patients with acute coronary syndrome (ACS), while some others are manifestations of cardiac disease rather than comorbidities.
Purpose
Our goal was to simplify comorbidity assessment in elderly non-ST-segment elevation ACS patients.
Methods
The study group consisted of 1 training (n=920, 76±7 years) and 1 testing (n=532; 84±4 years) cohorts. The end-point was all-cause mortality at 1-year follow-up. Comorbidities were assessed selecting those medical disorders other than cardiac disease that were independently associated with mortality by multivariable analysis.
Results
A total of 130 (14%) patients died in the training cohort. Six comorbidities were predictive: renal failure, anemia, diabetes, peripheral artery disease, cerebrovascular disease and chronic lung disease. The increase in the number of comorbidities yielded a gradient of risk on top of well-known clinical predictors: ≥3 comorbidities (27% mortality, HR=1.90, 95% CI 1.20–3.03, p=0.006); 2 comorbidities (16% mortality, HR=1.29, 95% CI 0.81–2.04, p=0.30); and 0–1 comorbidities (7.6% mortality, reference category). The discrimination accuracy (C-statistic= 0.80) and calibration (Hosmer-Lemeshow test, p=0.20) of the predictive model using the 6 comorbidities was comparable to the predictive model using the Charlson index (C-statistic=0.80; Hosmer-Lemeshow test, p=0.70). Similar results were reproduced in the testing cohort (≥3 comorbidities: 24% mortality, HR=2.37, 95% CI 1.25–4.49, p=0.008; 2 comorbidities: 14% mortality, HR=1.59, 95% CI 0.82–3.07, p=0.20; 0–1 comorbidities: 7.5% reference category).
Kaplan-Meyer curves for mortality
Conclusion
A simplified comorbidity assessment comprising 6 comorbidities provides useful risk stratification in elderly patients with ACS
Acknowledgement/Funding
This work was supported by grants from Spain's Ministry of Economy and Competitiveness through the Carlos III Health Institute
Collapse
Affiliation(s)
- M Soler Costa
- University Hospital Clinic of Valencia, Valencia, Spain
| | - J Nunez
- University Hospital Clinic of Valencia, Valencia, Spain
| | - V Ruiz
- University of Valencia, Facultad de Enfermería, Valencia, Spain
| | - C Bonanad
- University Hospital Clinic of Valencia, Valencia, Spain
| | - F Formiga
- University Hospital of Bellvitge, Unitat de Medicina Geriátrica, Barcelona, Spain
| | - E Valero
- University Hospital Clinic of Valencia, Valencia, Spain
| | | | - F Marin
- Hospital Clínico Univeristario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - A Ruescas
- University of Valencia, Fisioterapia, Valencia, Spain
| | - S Garcia Blas
- University Hospital Clinic of Valencia, Valencia, Spain
| | - G Minana
- University Hospital Clinic of Valencia, Valencia, Spain
| | - E Abu-Assi
- Hospital Alvaro Cunqueiro, Cardiology, Vigo, Spain
| | - H Bueno
- University Hospital 12 de Octubre, Cardiology, Madrid, Spain
| | - A Ariza-Sole
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - J Sanchis
- University Hospital Clinic of Valencia, Valencia, Spain
| |
Collapse
|
49
|
Esteve Pastor MA, Martin E, Alegre O, Castillo Dominguez JC, Formiga F, Martinez-Selles M, Diez-Villanueva P, Sanchis J, Ariza-Sole A, Marin F. P2525Relationship of Charlson Comorbidity Index with adverse events in elderly patients with Acute Coronary Syndromes: an analysis from LONGEVO-SCA Registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Elderly patients with Acute Coronary Syndromes (ACS) are under-represented in clinical trials and they have higher risk of new due their comorbidities. Charlson Comorbidity Index (CCI) is an established tool for evaluating the burden of comorbidity status and a high score of CCI is related with an increased risk of death.
Purpose
The aim of this study was to analyze the relationship of CCI in adverse outcomes at short-term follow-up in elderly patients admitted by an ACS.
Methods
The prospective multicenter LONGEVO-SCA included unselected elderly patients (≥80 years old) hospitalized after non-STACS. In this substudy, we analyze the influence of comorbidities, comparing the relationship between quartiles of CCI and adverse events at 6 months follow-up of CCI.
Results
We analyzed 520 patients (mean age 84.4±3.6 years; 320 (61.5%) male). 196 (37.6%) were classified into Q1, 105 (20.2%) into Q2, 93 (17.9%) into Q3 and 126 (24.2%) into Q4. No differences were observed in treatment at discharge across different quartiles for aspirin (p=0.648), beta-blockers (p=0.908) or statins (p=0.756). We observed a significant increase for all-cause mortality [9 (4.8%) vs 10 (10.2%) vs 11 (12.0%) vs 32 (26.0%); p<0.001] and readmissions [36 (18.4%) vs 21 (20%) vs 33 (35.5%) vs 48 (38.1%); p<0.001] respectively from Q1 to Q4. After Cox multivariate regression analysis, CCI was independently associated with mortality or readmissions [HR 1.15, 95% CI (1.06–1.26); p=0.001] and patients into high quartile had 6-fold risk of mortality [HR 6.19, 95% CI (2.95–12.99); p<0.001]. Kaplan Meier analysis showed that patients in the highest quartiles had significantly worse prognosis during the follow-up with high risk of all-cause mortality and readmissions (both p<0.001).
Event Free Survival according Charlson
Conclusions
In LONGEVO-SCA registry, we validated for the first time CCI as an independent factor related with adverse events. Patients into high quartiles of CCI had significantly worse prognosis during the follow-up and elderly patients into Q4 had 6-fold risk of mortality compared to Q1 patients.
Collapse
Affiliation(s)
- M A Esteve Pastor
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| | - E Martin
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| | - O Alegre
- University Hospital of Bellvitge, Barcelona, Spain
| | | | - F Formiga
- University Hospital of Bellvitge, Barcelona, Spain
| | | | | | - J Sanchis
- University Hospital Clinic of Valencia, Valencia, Spain
| | - A Ariza-Sole
- University Hospital of Bellvitge, Barcelona, Spain
| | - F Marin
- Hospital Clinico Univeristario Virgen de la Arrixaca, IMIB Arrixaca, CIBER-CV, Spain, Murcia, Spain
| |
Collapse
|
50
|
Sambola Ayala A, Anguita M, Elola J, Bernal JL, Fernandez C, Ferreiro JL, Bueno H, Marin F, Bonilla JL, Nunez-Villota J, Sanmartin M, Raposeiras S, Jimenez-Navarro MF, Filgueiras D, Ruiz-Ortiz M. P3605Lower benefit of women than men with ST-elevation myocardial infarction networks system in Spain: a study of 325,017 episodes over 10 years (2005–2015). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Sex differences are known to exist in the management of women presenting with ST elevation myocardial infarction (STEMI).Few studies have examined whether the clinical management and prognosis differs by sex when the STEMI network system is applied.
Purpose
To assess whether the STEMI network system improves management and prognosis both in men and women in Spain and to analyze possible differences according to sex.
Methods
We conducted a retrospective longitudinal study using information provided by the minimal database system (MDBS) of the Spanish National Health System (SNHS) to identify all hospitalizations in patients aged 35–94 years with the principal diagnosis of STEMI from 2005–2015. The risk-standardized in-hospital mortality ratio (RSMR) was defined as the ratio between predicted mortality and expected mortality, multiplied by the crude rate of mortality. The RSMR was calculated using multilevel risk adjustment models developed by the Medicare and Medicaid Services. The year of the development of organized systems of care for STEMI patients in the different Autonomous Communities was double-checked using data from the National Cardiac Catheterization and Interventional Cardiology Annual Registry. RSMR was used to compare outcomes related with gender and with the presence of regional AMI networks and the performance of PCI. Temporal trends for in-hospital mortality during the observed period were modeled using Poisson regression analysis with year as the only independent variable. In all models, incidence rate ratios (IRR) and their 95% confidence intervals (95% CI) were calculated.
Results
A total of 325,017 STEMI were identified among patients aged 35–94 years old. Of them 273,182 were selected after exclusions, and 106,277 (38.8%) were women. Women were on average 10 years older than men and had more comorbidities burden. The overall proportion of STEMI patients underwent to PCI increased, when a regional STEMI network was present from 2005–2015: (63.7% vs 48.2% in men; and 47.4% vs 32.9% in women; p<0.001). Differences in crude mortality between sexes was 15%, maintaining through 10 years, despite a higher increased of PCI (figure 1).However, women were less likely to be treated with PCI even though when STEMI network was stablished (63.7% vs 48.2% in men, 47.4% vs 32.9% in women, p<0.001) (figure 1).The mean crude in-hospital mortality rate for the whole study period was higher in women (9.3% vs 18.3%; unadjusted OR: 2.18, 95% CI: 2.12.-2.23, p<0.0001). RSMR was lower for women when STEMI network were working (17.7% vs. 19.7%; p<0.001).PCI and the presence of STEMI network were associated with a lower in-hospital mortality in STEMI women (adjusted OR, 0.48; 95% CI 0.41–0.52 and OR, 0.84; 95% CI 0.79–0.89, p<0.001, respectively).
Conclusions
Women were less likely to be treated with PCI and had higher in-hospital risk-adjusted mortality than men, despite the existence of STEMI network system.
Collapse
Affiliation(s)
| | - M Anguita
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| | - J Elola
- IMAS, Cardiology, Madrid, Spain
| | | | | | - J L Ferreiro
- University Hospital of Bellvitge, Cardiology, Barcelona, Spain
| | - H Bueno
- University Hospital 12 de Octubre, Cardiology, Madrid, Spain
| | - F Marin
- Hospital Universitario Virgen de la Arrixaca, Cardiology, Murcia, Spain
| | - J L Bonilla
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| | - J Nunez-Villota
- University Hospital Clinic of Valencia, Cardiology, Valencia, Spain
| | - M Sanmartin
- University Hospital Ramon y Cajal de Madrid, Cardiology, Madrid, Spain
| | - S Raposeiras
- Complejo Hospitalario Universitario de Vigo., Cardiology, Vigo, Spain
| | | | - D Filgueiras
- Hospital Clinic San Carlos, Cardiology, Madrid, Spain
| | - M Ruiz-Ortiz
- University Hospital Reina Sofia, Cardiology, Cordoba, Spain
| |
Collapse
|